Report Sections

See All Reports

Coronavirus Infections (808) Severe Acute Respiratory Syndrome (560) Infection (466) Pneumonia (365) Communicable Diseases (197) Respiratory Distress Syndrome, Adult (178) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) (130) Syndrome (105) Virus Diseases (87) Pneumonia, Viral (82) Depression (65) Critical Illness (62) Anxiety Disorders (38) Respiratory Tract Infections (36) Cardiovascular Diseases (35) Emergencies (35) Stress, Psychological (31) Lung Injury (30) Neoplasms (30) Inflammation (29) Stress Disorders, Post-Traumatic (29) Wounds and Injuries (29) Hypoxia (28) Thrombosis (28) Diabetes Mellitus (26) Disease (25) Respiratory Tract Diseases (25) Stress Disorders, Traumatic (25) Depressive Disorder (24) Acute Kidney Injury (22) Disease Progression (22) Lung Diseases (22) Mental Disorders (21) Burnout, Psychological (19) Olfaction Disorders (19) Respiration Disorders (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Fibrosis (12) Arthritis, Rheumatoid (11) Influenza, Human (11) Rheumatic Diseases (11) Venous Thrombosis (11) Dyspnea (10) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Heart Failure (8) Infarction (8) Liver Diseases (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lung Diseases, Obstructive (7) Lymphopenia (7) Multiple Sclerosis (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Pulmonary Disease, Chronic Obstructive (6) Autoimmune Diseases (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Nervous System Diseases (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Adenoviridae Infections (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Colorectal Neoplasms (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypertension, Pulmonary (3) Ischemia (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Initiation and Maintenance Disorders (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Ageusia (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Bacteremia (2) Behcet Syndrome (2) Bipolar Disorder (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) (2) Dementia (2) Depressive Disorder, Major (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Eye Diseases (2) Fever (2) Fibromyalgia (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypersensitivity (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) (1) Common Cold (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronavirus Infect (1) (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) Developmental Disabilities (1) DiGeorge Syndrome (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal Neoplasms (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophies (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Reperfusion Injury (1) Resp (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D002318: Cardiovascular Diseases

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (72)


Name (Synonyms) Correlation
drug752 Cholecalciferol Wiki 0.30
drug745 Chloroquine or hydroxychloroquine Wiki 0.24
drug739 Chloroquine Wiki 0.21
Name (Synonyms) Correlation
drug746 Chloroquine phosphate Wiki 0.20
drug539 CAP-1002 Wiki 0.17
drug2943 Saline nasal and throat spray Wiki 0.17
drug682 Cannabidiol, pharmaceutically produced with < 5 ppm THC Wiki 0.17
drug711 Centrum Adult (under 50) multivitamin Wiki 0.17
drug726 Change in preference to surgery under COVID-19 pandemic. Wiki 0.17
drug3158 Standard supportive care Wiki 0.17
drug3630 YinHu QingWen Decoction(low dose) Wiki 0.17
drug709 Cenicriviroc (CVC) Wiki 0.17
drug789 Cognitive training Wiki 0.17
drug32 1: discontinuation of RAS blocker therapy Wiki 0.17
drug4032 standard western medicine treatment Wiki 0.17
drug747 Chlorpromazine Wiki 0.17
drug290 Assessment of cardiovascular diseases and cardiovascular risk factors Wiki 0.17
drug2820 Reverse-transcription polymerase chain reaction (RT-PCR) Wiki 0.17
drug702 Cash transfer Wiki 0.17
drug2589 PreserVision AREDS formulation gel tabs Wiki 0.17
drug698 Carrageenan nasal and throat spray Wiki 0.17
drug714 Certified cloth face mask plus preventive information Wiki 0.17
drug2707 RAAS inhibitor [continued standard of care] Wiki 0.17
drug44 2: continuation of RAS blocker therapy Wiki 0.17
drug733 Chest physiotherapy using a non-invasive oscillating device Wiki 0.17
drug2435 Physical exercise training Wiki 0.17
drug756 Ciclesonide Metered Dose Inhaler [Alvesco] Wiki 0.17
drug696 Caring Contacts Wiki 0.17
drug736 Chiropractic care Wiki 0.17
drug697 Carotid Artery Reactivity Testing Wiki 0.17
drug2203 Non-invasive cardiac imaging Wiki 0.17
drug3234 Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) Wiki 0.17
drug3278 Tele-medicine platform Wiki 0.17
drug1137 Electrocardiogram, telemetry, echocardiogram, laboratory values Wiki 0.17
drug700 Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients. Wiki 0.17
drug4082 zinc Wiki 0.17
drug3629 YinHu QingWen Decoction Wiki 0.17
drug1030 Digital cardiac Counseling Wiki 0.17
drug3901 non Wiki 0.17
drug220 Angiotensin II Receptor Blockers Wiki 0.17
drug735 Chinese medicine treatment Wiki 0.17
drug3906 non-interventional Wiki 0.17
drug731 Chest computed tomography (CT) Wiki 0.17
drug692 Cardiac surgery Wiki 0.17
drug3303 Temporarily holding the RAAS inhibitor [intervention] Wiki 0.17
drug2427 Phone-call screening and management by a medical student/general practitioner tandem Wiki 0.17
drug2592 Preventive information Wiki 0.17
drug751 Choices and judgements Wiki 0.17
drug713 Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies Wiki 0.17
drug753 ChulaCov19 mRNA vaccine Wiki 0.17
drug2185 No interverntion Wiki 0.17
drug581 COVID visitation restrictions Wiki 0.17
drug681 Cannabidiol Wiki 0.12
drug222 Angiotensin converting enzyme inhibitor Wiki 0.12
drug46 300 mg of omega3-FA Wiki 0.12
drug754 Ciclesonide Wiki 0.12
drug1503 Hydroxychloroquine Sulfate Regular dose Wiki 0.12
drug56 50 mg/mL Virazole Wiki 0.12
drug1502 Hydroxychloroquine Sulfate Loading Dose Wiki 0.12
drug1570 Icosapent ethyl Wiki 0.12
drug25 100 mg/mL Virazole Wiki 0.12
drug617 COVID-19 exposure Wiki 0.12
drug742 Chloroquine Sulfate Wiki 0.12
drug767 Clinical data Wiki 0.10
drug3918 observational Wiki 0.10
drug2340 PLACEBO Wiki 0.10
drug3285 Telemedicine Wiki 0.08
drug1166 Enoxaparin Wiki 0.04
drug2448 Placebo Wiki 0.04
drug2514 Placebo oral tablet Wiki 0.03
drug2782 Remdesivir Wiki 0.03
drug1472 Hydroxychloroquine Wiki 0.02

Correlated MeSH Terms (34)


Name (Synonyms) Correlation
D006333 Heart Failure NIH 0.18
D019965 Neurocognitive Disorders NIH 0.17
D013896 Thoracic Diseases NIH 0.17
Name (Synonyms) Correlation
D000787 Angina Pectoris NIH 0.17
D050197 Atherosclerosis NIH 0.17
D003327 Coronary Disease NIH 0.17
D054143 Heart Failure, Systolic NIH 0.17
D014029 Tobacco Use Disorder NIH 0.17
D015428 Myocardial Reperfusion Injury NIH 0.17
D015427 Reperfusion Injury NIH 0.17
D006331 Heart Diseases NIH 0.13
D050177 Overweight NIH 0.12
D000073296 Noncommunicable Diseases NIH 0.12
D009202 Cardiomyopathies NIH 0.10
D054058 Acute Coronary Syndrome NIH 0.08
D003324 Coronary Artery Disease NIH 0.08
D006973 Hypertension NIH 0.08
D003693 Delirium NIH 0.08
D002908 Chronic Disease NIH 0.08
D001523 Mental Disorders NIH 0.07
D008173 Lung Diseases, Obstructive NIH 0.06
D000066553 Problem Behavior NIH 0.06
D009203 Myocardial Ischemia NIH 0.05
D008171 Lung Diseases, NIH 0.04
D014947 Wounds and Injuries NIH 0.03
D012141 Respiratory Tract Infections NIH 0.03
D003141 Communicable Diseases NIH 0.02
D007239 Infection NIH 0.02
D016638 Critical Illness NIH 0.02
D011024 Pneumonia, Viral NIH 0.02
D013577 Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.01
D011014 Pneumonia NIH 0.01
D045169 Severe Acute Respiratory Syndrome NIH 0.01

Correlated HPO Terms (13)


Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.99
HP:0001635 Congestive heart failure HPO 0.18
HP:0001681 Angina pectoris HPO 0.17
Name (Synonyms) Correlation
HP:0002621 Atherosclerosis HPO 0.17
HP:0001638 Cardiomyopathy HPO 0.10
HP:0001677 Coronary artery atherosclerosis HPO 0.08
HP:0000822 Hypertension HPO 0.08
HP:0006536 Pulmonary obstruction HPO 0.06
HP:0000708 Behavioral abnormality HPO 0.06
HP:0001658 Myocardial infarction HPO 0.05
HP:0002088 Abnormal lung morphology HPO 0.04
HP:0011947 Respiratory tract infection HPO 0.03
HP:0002090 Pneumonia HPO 0.01

Clinical Trials

Navigate: Correlations   HPO

There are 35 clinical trials


1 Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China

Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

NCT04255940
Conditions
  1. Cardiovascular Death; Major Adverse Cardiovascular Events
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Cardiovascular Death

Time: 3 months

Secondary Outcomes

Measure: Major Adverse Cardiovascular Events

Time: 3 months

Measure: Times From symptom onset to hospital arrival

Time: 3 months

Measure: Anxiety

Time: 3 months
2 Retrospective Study of Myocardial Damage in COVID-19

This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

NCT04312464
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
Interventions
  1. Other: non
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The myocardial injury incidence of COVID-19 patients

Measure: The myocardial injury incidence

Time: 75 days

Description: The risk factors analysis for the death of COVID-19 patients

Measure: The risk factors analysis for the death

Time: 75 days

Secondary Outcomes

Description: The clinical characteristics description of COVID-19 patients

Measure: Clinical characteristics

Time: 75 days

Description: The clinical course description of COVID-19 patients

Measure: Clinical course

Time: 75 days

Description: The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patients

Measure: Cardiovascular comorbidity

Time: 75 days

Description: Analysis of causes of death in COVID-19 patients

Measure: Analysis of causes of death

Time: 75 days
3 Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.

NCT04324684
Conditions
  1. Pneumonia, Viral
  2. Hypertension
  3. Diabetes Mellitus
  4. Obesity
  5. Cardiovascular Diseases
  6. Obstructive Lung Disease
MeSH:Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive Cardiovascular Diseases
HPO:Abnormal lung morphology Abnormality of the cardiovascular system Pneumonia Pulmonary obstruction

Primary Outcomes

Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

Measure: rate of recovery

Time: 3 weeks

Secondary Outcomes

Description: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

Measure: time to improvement

Time: 3 weeks

Description: the efficacy of different pharmaceutical treatment against Covid-19

Measure: efficacy of treatments

Time: 3 weeks

Description: liver, kidney or multiorgan failure, cardiac failure

Measure: organ failure

Time: 3 weeks
4 Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY

CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.

NCT04325412
Conditions
  1. COVID-19; Cardiovascular Diseases
MeSH:Coronavirus Infections Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: The incidence of cardiovascular complications in patients with COVID-19

Time: 30 days
5 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

NCT04325867
Conditions
  1. Angina Pectoris
  2. Acute Coronary Syndrome
  3. Coronary Syndrome
  4. Coronary Artery Disease
  5. Angioplasty
  6. Stent Restenosis
  7. Hypertension
  8. Heart Failure, Systolic
  9. Depression, Anxiety
  10. Covid-19
  11. Isolation, Social
Interventions
  1. Other: Tele-medicine platform
MeSH:Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome
HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Myocardial infarction Right ventricular failure

Primary Outcomes

Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

Time: 6 months

Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

Measure: Number of patients included in this platform

Time: 6 months

Secondary Outcomes

Description: Will be the number of sessions per patient multiplied with the number of patients included

Measure: Number of consultations/sessions given

Time: 6 months
6 Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

NCT04327479
Conditions
  1. Cardiovascular Diseases
  2. Cardiovascular Risk Factor
  3. SARS
Interventions
  1. Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: mortality of any cause

Measure: All-cause mortality

Time: During 1 year follow-up

Secondary Outcomes

Description: mortality of any cause

Measure: 30-day mortality

Time: Within 30 days after inclusion

Description: Myocardial infarction, stroke, or CV death

Measure: Major adverse cardiovascular events

Time: During 1 year follow-up
7 ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study

Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19. Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death. Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19. It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.

NCT04329195
Conditions
  1. History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
Interventions
  1. Drug: 1: discontinuation of RAS blocker therapy
  2. Drug: 2: continuation of RAS blocker therapy
MeSH:Infection Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)

Time: from day 0 to day 28 or hospital discharge

Secondary Outcomes

Measure: Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28

Time: at day 28

Measure: Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.

Time: at days 7, 14 and 28

Measure: Number of days alive free of oxygen.

Time: from day 0 to day 28 or hospital discharge

Measure: Number of days alive outside hospital until day28

Time: at day28

Measure: Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28

Time: at day28

Measure: Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28

Time: at day28

Measure: Number of days alive free of ICU admission until day28

Time: at day28

Measure: Rate of all-cause mortality at day 28

Time: at day 28

Measure: Rate of cardiovascular death at day 28

Time: at day 28

Measure: Number of days alive free of acute kidney injury until hospital discharge

Time: at day 28 to hospital discharge
8 Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19

Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.

NCT04331574
Conditions
  1. COVID-19
  2. Hypertension
  3. Cardiovascular Diseases
MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension

Primary Outcomes

Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.

Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19

Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

Secondary Outcomes

Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity

Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity

Time: 3 months
9 Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in December of 2019. Since then, the disease has spread rapidly around the globe, accounting for thousands of deaths in multiple countries. On March 11th, 2020, the World Health Organization declared COVID-19 as a pandemic. Although COVID-19 manifests primarily as a respiratory illness, several cardiovascular implications have been reported related to its natural course and treatment. Its exact effect on the cardiovascular system though is currently unknown. Therefore, we propose a retrospective, observational, case-control study looking for cardiovascular manifestations of COVID-19, including laboratory evidence of myocardial injury, electrocardiographic changes, arrhythmias and echocardiographic abnormalities. Hospitalized patients admitted with fever, cough, sore throat, and/or dyspnea who were tested positive for SARS-CoV-2 will be included in our study and will be matched based on their age and gender with patients admitted with similar symptoms who tested negative for SARS-CoV-2. The electronic medical charts of the study subjects will be reviewed and relevant demographic, clinical, laboratory and imaging findings will be deidentified and recorded. Since our study will be a retrospective chart review study it carries minimal risk for the patients and the investigators. Cardiovascular disease associated with COVID-19 might be contributing to the high mortality rates and its recognition will allow for prevention, early diagnosis and appropriate treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.

NCT04335630
Conditions
  1. Cardiovascular Diseases
  2. COVID
Interventions
  1. Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.

Time: One year

Secondary Outcomes

Measure: Prevalence of pericarditis, pericardial effusion, valvular disease.

Time: One year

Measure: Identification of characteristic electrocardiographic patterns related to COVID-19

Time: One year

Measure: Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.

Time: One year

Measure: Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19

Time: One year

Measure: Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19

Time: One year

Measure: Role of insurance type on clinical outcomes of patients with COVID-19

Time: One year

Measure: Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications

Time: One year

Measure: Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications

Time: One year
10 The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.

NCT04340921
Conditions
  1. Cardiovascular Disease Acute
  2. Cardiomyopathies
  3. COVID
Interventions
  1. Biological: COVID-19 exposure
MeSH:Cardiovascular Diseases Cardiomyopathies
HPO:Abnormality of the cardiovascular system Cardiomyopathy

Primary Outcomes

Description: T-cell immunophenotype

Measure: T-cell immunophenotype

Time: 12 months from enrollment

Secondary Outcomes

Description: death, survival to discharge

Measure: Mortality

Time: 12 months from enrolment

Description: Admission to the intensive care

Measure: ITU admission

Time: 12 months from enrolment

Description: Defined by troponin rise to >99th centile

Measure: Myocardial injury

Time: 12 months from enrolment
11 Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial

Following the announcement of the containment of the population due to the COVID-19 epidemic on March 17, 2020 in France, a notable decrease in the number of consultations in general practice was reported. Patients no longer contact their general practitioner, including those with regular follow-up for one or more chronic conditions. This observation raised worries since it could lead to delay or failure in detecting decompensations / complications of these chronic conditions by a lack of recourse to care. Thus, an urgent message from the National Health Department (Direction Générale de la Santé - DGS) was adressed on April 8, 2020 to the health professionals regarding the organization of care aside from COVID-19. The main recommendation was "that the personal physician or the corresponding specialist should contact the most fragile patients with chronic condition to ensure follow-up and detect any risk of decompensation ". Such fragile patients are in great numbers, up to more than 200 for an average general practitioner. Therefore, although this recommendation is regarded as "essential in view of the health needs of the population", it will prove quite difficult to follow without the help of a skilled external assistance that can be quickly mobilized. The COVIQUEST project is a cluster randomized trial in general practice designed to assess the optimizationg of the screening and management of patients with chronic condition at risk of decompensation through a collaboration between the general practitioner and a medical student. The trial will focus on patients wit cardiovascular conditions aged 70 or more and patients with mental health conditions. These conditions are both highly prevalent in general practice and both at risk of severe short-term complications. Practices will be randomly assigned to a group (A or B). In group A, students will start by contacting patients with cardiovascular conditions; in group B they will start by contacting patients patients with mentral health conditions. The students will call these patients on the phone and ask them specific questions about their health, their needs, and if they want their general practitioner to call them back. The student will then transmit this information to the general practitioner who will decide on the best care to offer the patient. The primary outcome is defined as the occurrence of hospitalization during a one-month period after the phone call. It will be collected by a second phone call from the medical student. This time, all patients will be contacted, i.e. both patients with mental illness and cardiovascular patients, whatever the group. Thus, patients allocated to the control groups (i.e. patients with mental illness from group A and cardiovascular patients from group B) will also benefit from the intervention at 1 month: again, students will ask patients about their health and whether they want their general practitioner to call them back. This approach has several advantages: 1. all patients will benefit from a phone call, in accordance with the recommendations of the DGS, 2. the involvement of students, competent in medical interviews and quickly mobilizable, will help general practitioners, on the front line of many missions, without any health risk linked to the contagiousness of COVID-19 for students, 3. randomizing the call order will allow to assess with a high level of evidence the impact of such an organization on hospitalizations, for two families of diseases with high prevalence. The trial will involve at least nine French regions. Considering that the general practitioner's patient base numbers an average of 110 patients with chronic cardiovascular disease or chronic mental illness, and that at least 25 general practitioners per region participate in the study, we can expect that 22,000 patients will benefit from the intervention of this study.

NCT04359875
Conditions
  1. Cardiovascular Diseases
  2. Mental Disorder
Interventions
  1. Behavioral: Phone-call screening and management by a medical student/general practitioner tandem
MeSH:Cardiovascular Diseases Mental Disorders
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Hospitalization over a one month period. The primary outcome will be collected by a phone call from a medical student to the patient 1 month after randomization date. Hospitalizations (date, location, length, if available, and reason) will be collected. Because there will be many patients to be called for each practitioner, we expect these phone call to occur within a few days after day 28.

Measure: Hospitalization(s) at 1 month

Time: 1 month

Secondary Outcomes

Description: In the experimental group only: proportion of patients for whom the practitioner had to call back after the medical student had phoned (just after allocation of the practice to the experimental group) at 1 month.

Measure: Phone-call from the general practitioner (in the experimental group only)

Time: 1 month

Description: Mortality will be reported after checking with the city of the patient's home if there is no response to the phone call

Measure: Mortality at 1 month

Time: 1 month

Description: Number of general practitioner consultations and teleconsultations (and time of general practitioner consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

Measure: Use of primary care

Time: 6 months

Description: Number of consultations with another medical specialist (and time of consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

Measure: Use of secondary care

Time: 6 months

Description: Number of prescriptions related to the chronic disease that were dispensed by the pharmacy using data from the French Health National (SNDS) Database

Measure: Number of prescriptions related to the chronic disease dispensed by the pharmacy

Time: 6 months

Description: Number of hospitalizations using data from the French Health National (SNDS) Database

Measure: Number of hospitalization(s)

Time: 6 months

Description: Time to hospitalization using data from the French Health National (SNDS) Database

Measure: Time to hospitalization(s)

Time: 6 months

Description: Hospitalization duration using data from the French Health National (SNDS) Database

Measure: Hospitalization(s)' durations

Time: 6 months

Description: Reason for hospitalization using data from the French Health National (SNDS) Database

Measure: Reasons for hospitalization(s)

Time: 6 months

Description: Number of deaths using data from the French Health National (SNDS) Database

Measure: Mortality at 6 months

Time: 6 months

Description: Only for patients in the COVIQuest_CV sub-trial: Cardiovascular events (MACE): nonfatal stroke, nonfatal myocardial infarction, cardiovascular death and hospitalization for heart failure using data from the French Health National (SNDS) Database

Measure: Cardiovascular events (MACE)

Time: 6 months

Description: Only for patients in the COVIQuest_MH sub-trial: Psychotropic drugs consumption using data from the French Health National (SNDS) Database

Measure: Psychotropic drugs

Time: 6 months
12 Long-term Effects of Coronavirus 2019 Disease on the Cardiovascular System in Patients Who Have Undergone a Diagnostic Nasopharyngeal Swab for SARS-CoV-2. CV COVID-19 Registry

Patients presenting with the coronavirus-2019 disease (COVID-19) have a very high risk of cardiovascular adverse events, including death from cardiovascular causes. Unfortunately, there are no reliable statistics on the frequency and severity of these complications during the index hospitalization. Moreover, the long-term cardiovascular outcomes of these patients are entirely unknown. The investigators aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and determine their long-term cardiovascular outcomes.

NCT04359927
Conditions
  1. Sars-CoV2
  2. Covid19
  3. Cardiovascular Diseases
  4. Cardiovascular Risk Factor
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Cardiovascular mortality is defined according to the Academic Research Consortium-2 and will be independently adjudicated by a Clinical Events Committee.

Measure: Cardiovascular mortality

Time: 1-year

Secondary Outcomes

Description: Acute myocardial infarction is defined according to the Academic Research Consortium-2.

Measure: Acute myocardial infarction

Time: 1-year

Description: Stroke is defined according to the Academic Research Consortium-2.

Measure: Stroke

Time: 1-year

Other Outcomes

Description: Documented hospital admission due to heart failure

Measure: Heart failure hospitalization

Time: 1-year

Description: Documented by a chest computed tomography

Measure: Pulmonary embolism

Time: 1-year

Description: Documented hospital admission due to any cardiac arrhythmia

Measure: Cardiac arrhythmias

Time: 1-year
13 How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic

A dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.

NCT04369690
Conditions
  1. COVID-19
  2. Chronic Disease
  3. Psychiatric Disorder
  4. Cardiovascular Diseases
MeSH:Cardiovascular Diseases Chronic Disease Mental Disorders Problem Behavior
HPO:Abnormality of the cardiovascular system Behavioral abnormality

Primary Outcomes

Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)

Measure: Mental health - Stress

Time: through study completion, estimated to 8 months

Description: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)

Measure: Mental health - Anxiety

Time: through study completion, estimated to 8 months

Description: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)

Measure: Mental health - Depression

Time: through study completion, estimated to 8 months

Secondary Outcomes

Description: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)

Measure: Moral distress in healthcare workers

Time: through study completion, estimated to 8 months

Description: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)

Measure: Moral resilience in healthcare workers

Time: through study completion, estimated to 8 months

Description: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)

Measure: Social life

Time: through study completion, estimated to 8 months

Description: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)

Measure: COVID-9 symptoms

Time: through study completion, estimated to 8 months

Description: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Adverse health long-term outcome

Time: 5 years before the outbreak and two years after

Description: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Inpatient

Time: 5 years before the outbreak and two years after

Description: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - ER

Time: 5 years before the outbreak and two years after

Description: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Outpatient

Time: 5 years before the outbreak and two years after

Description: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)

Measure: Sleep

Time: through study completion, estimated to 8 months
14 Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19

Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.

NCT04374110
Conditions
  1. COVID
  2. Hypertension
  3. Cardiovascular Diseases
  4. Cardiovascular Risk Factor
Interventions
  1. Other: Clinical data
MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension

Primary Outcomes

Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Measure: Adverse events

Time: through study completion, an average of 2 weeks

Secondary Outcomes

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: through study completion, an average of 2 weeks

Description: Ventilation during hospitalization

Measure: Ventilation during hospitalization

Time: through study completion, an average of 2 weeks

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: prolonged follow up, through study completion, an average of one year
15 A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer

The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. In addition, serologic markers of more severe disease including coagulation abnormalities and thrombocytopenia, are not uncommon among patients hospitalized with severe COVID-19 infection and are more common in patients who died in-hospital. As the COVID-19 pandemic continues to grow, there is a pressing need to identify safe, effective, and widely available therapies that can be scaled and rapidly incorporated into clinical practice. Understanding the putative mechanism of increased mortality risk associated with abnormal coagulation function and cardiac injury is critical to guide studies of promising therapeutic interventions. Published and anecdotal reports indicate that endothelial dysfunction and thrombosis are common in critically ill patients with COVID-19, including reports of diffuse microvascular thrombosis in the lungs, heart, liver, and kidneys. Patients with cardiovascular disease (CVD) and CVD risk factors are known to have endothelial dysfunction and a heightened risk of thrombosis. A recent study of COVID-19 inpatients from Wuhan, China observed that an elevated D-dimer level greater than 1 ug/mL was associated with an 18 times higher risk of in-hospital death, underscoring the importance of increased coagulation activity as a potential modifiable risk marker that may drive end-organ injury. Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease, and the association between coagulopathy and adverse outcomes in patients with sepsis, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy and safety.

NCT04377997
Conditions
  1. Cardiovascular Diseases
  2. COVID-19
Interventions
  1. Drug: Enoxaparin
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Aim 1 - Risk of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

Measure: Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

Time: 12 weeks

Description: Aim 2 - Risk of major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

Measure: Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

Time: 12 weeks
16 COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry

Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry. Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.

NCT04390555
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
  3. Cardiovascular Risk Factor
  4. Heart Failure
MeSH:Heart Failure Cardiovascular Diseases
HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Congestive heart failure Right ventricular failure

Primary Outcomes

Description: All-cause and cardiovascular mortality during index hospitalization.

Measure: In-hospital mortality.

Time: Hospitalization period, assessed up to 30 days

Secondary Outcomes

Description: The duration of hospitalization on the intensive care unit.

Measure: The length of stay in the intensive care unit.

Time: Hospitalization period in the ICU, assessed up to 30 days

Description: The total length of stay in the hospital.

Measure: The duration of hospitalization.

Time: Hospitalization period, assessed up to 30 days

Measure: The need and duration of invasive mechanical ventilation.

Time: Hospitalization period, assessed up to 30 days

Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.

Time: 3 months

Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.

Time: 6 months
17 Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)

Most patients undergoing a cardiovascular procedure need an ICU-bed during the hospitalization and therefore it is possible that for the unforeseen future, because of the Covid-19 crisis, many patients will stay on the waiting list for many months to come. There are some studies showing an increased mortality associated with an increased waiting time for the patients on the waiting list for an elective cardiac surgery. However, there is no data on the evolution of the morbidity, the quality of life and the symptomatology of the patients waiting for an elective operation. Also it is not clear whether the period of waiting for an elective cardiovascular operation would impact the morbidity or the mortality of the planned operation at later stage. Furthermore, there is a plethora of studies on risk factors associated with the perioperative morbidity and mortality in general. Therefore, the rationale of the current study is to evaluate whether Digital Cardiac Counseling (DCC) would improve outcomes of the patients waiting for an elective cardiac operation. At the DCC platform, there will be assessments of cardiovascular symptoms, Covid-19 prevention for cardiovascular patients, smoking cessation, anxiety relief, exercise stimulation, pulmonary rehabilitation and diet adjustments. This will be done by means of questionnaires and E-consults.

NCT04393636
Conditions
  1. Cardiovascular Diseases
  2. Cardiovascular Risk Factor
Interventions
  1. Other: Digital cardiac Counseling
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

Measure: MACEs

Time: Cumulative incidence (from inclusion) at 1 year postoperatively

Secondary Outcomes

Description: all-cause mortality

Measure: Mortality

Time: Before the scheduled date of the operation, at 30 days, in-hospital (at 30 days or during the same hospitalization for the planned procedure), at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Mortality caused by cardiovascular disease

Measure: Cardiovascular-related mortality

Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Mortality caused by Covid-19 infection and/or related complications

Measure: Covid-19 related mortality

Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Measured using SF (Short Form) 36 Health Survey

Measure: Health-related quality of life

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: New York Heart Association Functional Classification

Measure: NYHA Functional classification

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Grading of angina pectoris

Measure: CCS (Canadian Cardiovascular Society grading of angina pectoris)

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

Measure: MACEs

Time: during waiting time measured before the scheduled date of the operation, at 1-year postoperatively

Description: Respiratory failure, pneumonia, septicemia, renal failure, myocardial infarction, stroke, atrial fibrillation, pacemaker implantation, re-operation, delirium, wound infection, urinary tract infection and pressure ulcers

Measure: Perioperative complications

Time: during waiting time measured before the scheduled date of the operation, at 30 days postoperatively and at 90 days postoperatively

Description: from surgery until discharge in days

Measure: Hospital length of stay

Time: from the admission to the hospital untill discharge from the hospital, assessed up to 12 months

Description: measured in hours from arrival in ICU until extubation

Measure: Time on mechanical ventilation

Time: from the admission to the ICU untill discharge from the ICU, assessed up to 12 months

Description: whether patient is active smoking

Measure: Smoking status

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Measured using HADS (Hospital Anxiety and Depression Scale) score

Measure: Anxiety and Depression

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: the percentage of patients taking part in postoperative cardiac rehabilitation

Measure: Participation in postoperative cardiac rehabilitation

Time: postoperatively at 3 months, at 6 months and at 12 months

Description: Percentage BMI<20 or BMI>30

Measure: Body-Mass Index (BMI)

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Unplanned visits to emergency department

Measure: Number of participants with unplanned visits

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Total costs of the whole treatment process

Measure: Healthcare costs

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months
18 Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19

The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

NCT04397939
Conditions
  1. COVID-19
  2. Myocardial Reperfusion Injury
  3. Cardiovascular Diseases
MeSH:Cardiovascular Diseases Reperfusion Injury Myocardial Reperfusion Injury Wounds and Injuries
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Number of death during hospitalization

Measure: Number of In-Hospital Death

Time: During hospitalization, average 2-3 weeks

Secondary Outcomes

Description: Length of stay in the hospital

Measure: Length of Stay

Time: During hospitalization, average 2-3 weeks

Description: Successful treatment will be defined by two consecutive negative tests for COVID-19

Measure: Number of Successful Treatment

Time: During hospitalization, average 2-3 weeks
19 STATIN THERAPY AND COVID-19 INFECTION (STACOV PROJECT)

Considering that simvastatin, and probably statins in general, interfere with SARS-cov-2 cellular uptake and some inflammatory pathways activated by the virus, those patients on statin therapy should be less vulnerable to infection and their clinical course and prognosis should be better than that in individuals not on statin therapy.

NCT04407273
Conditions
  1. COVID
  2. Statin
  3. Cardiovascular Diseases
Interventions
  1. Drug: observational
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Assess the difference in the WHO SARS-cov-2 scale of severity (9 steps) achieved by Covid-19 infected patients, admitted in the hospital, with and without background statin therapy comparable in age and gender distribution

Measure: SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy

Time: at the time of admission
20 Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury

Cardiac Troponin elevation is associated with adverse prognosis in COVID-19. The MIIC-MI study aims to investigate mechanisms of cardiac injury in COVID-19 using multi-modality imaging and immunophenotyping to better understand the link with adverse patient outcomes.

NCT04412369
Conditions
  1. COVID19
  2. Cardiovascular Diseases
Interventions
  1. Diagnostic Test: Non-invasive cardiac imaging
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.

Time: Baseline

Secondary Outcomes

Measure: Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging

Time: Baseline

Measure: Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging

Time: Baseline
21 Qatar Cardiovascular COVID-19 Registry

The novel coronavirus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID -19), is highly contagious in the community and has resulted in a global pandemic. This infection has a special implication on the patient who complains from cardiac disease or acute cardiovascular condition and may result in cardiovascular complications such as myocardial infarction. For this end, we target to study this group of patient, who has a cardiac disease with COVID-19 in Qatar, in addition, the acute myocardial infarction with COVID-19 from the Gulf countries and collect all the related data to come with a comprehensive view about those patients.

NCT04430374
Conditions
  1. Cardiovascular Diseases
Interventions
  1. Other: No interverntion
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The outcome of this registry will be: entire information about the patients who admitted with COVID-19 accompany with a cardiovascular condition in Qatar. Additionally, a comparison will be conducted between the cardiac patient who admitted over the period February to December to December 2020 and the same category of patients over the same period of 2019 in Qatar to figure out the reason behind the dropping of the number of the patient. A multicenter data from the Gulf countries for Acute MI patients infected with COVID-19. A comparison between our patients (either in Qatar only or the entire Gulf) populations and the outcome of other international registries such as the NACMI (US registry)

Measure: The impact of COVID-19 on cardiovascular patient

Time: 2 month from starting date
22 WHF COVID-19 and Cardiovascular Disease Survey

A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

NCT04475471
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for major adverse cardiovascular events (MACE)

Time: Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.

Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]

Time: at discharge and 30-day follow-up visits from the hospital admission date.

Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)

Time: at discharge and 30-day follow-up visits from the hospital admission date.

Description: Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke

Measure: All cause deaths

Time: any time during the hospital admission and at 30-day follow-up.
23 Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients

Non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after SARS-CoV-2 infection in adults.

NCT04492384
Conditions
  1. Covid19
  2. SARS-CoV-2 Infection
  3. Pneumonia
  4. Copd
  5. CKD
  6. Cardiac Event
  7. Overweight and Obesity
  8. Cardiovascular Diseases
  9. Diabetes
  10. Hypertension
  11. Coronary Heart Disease
Interventions
  1. Other: non-interventional
MeSH:Infection Communicable Diseases Cardiovascular Diseases Heart Diseases Coronary Disease Overweight Noncommunicable Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: percentage of patients with non-infectious diseases relating to overall number of patients registered in study

Measure: rate of non-infectious diseases

Time: 12 month since a moment of request of medical help

Description: correlation between number of patients with COVID-19 of various severity and number of pre-existing conditions and their severity among these groups

Measure: severity of COVID-19 depending on pre-existing diseases

Time: 12 month since a moment of request of medical help

Description: Registration of disability or change of disability status

Measure: disability registration / change of disability status

Time: 12 month since a moment of request of medical help

Description: rate of deaths among registered participants

Measure: rate of letal outcomes

Time: 12 month since a moment of request of medical help

Description: correlation between number of deaths and pre-existing diseases

Measure: rate of letal outcomes depending on pre-existing disease

Time: 12 month since a moment of request of medical help
24 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)

MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).

NCT04505098
Conditions
  1. Covid19
  2. Atherosclerosis
  3. Cardiovascular Diseases
  4. Upper Respiratory Tract Infections
Interventions
  1. Drug: Icosapent ethyl
MeSH:Respiratory Tract Infections Cardiovascular Diseases Atherosclerosis
HPO:Abnormality of the cardiovascular system Atherosclerosis Respiratory tract infection Type IV atherosclerotic lesion

Primary Outcomes

Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.

Measure: Percentage of patients with moderate or severe confirmed viral URIs

Time: 0-12 months

Description: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)

Measure: Worst clinical status due to a confirmed viral URI

Time: 0-12 months

Other Outcomes

Measure: Percentage of participants who die due to any cause

Time: 0-12 months

Description: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

Measure: Percentage of participants experiencing a major adverse cardiovascular event

Time: 0-12 months

Description: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)

Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event

Time: 0-12 months

Measure: Percentage of participants who are hospitalized for heart failure

Time: 0-12 months

Measure: Percentage of participants who are hospitalized for any reason

Time: 0-12 months

Measure: Percentage of participants who have an emergency department visit for any reason

Time: 0-12 months
25 Investigating the Association Between Smoking Status and COVID-19 Outcomes: Collecting Data From Health Systems Affiliated With the National Cancer Institute's Cancer Center Cessation Initiative (C3I)

This cohort study will obtain electronic health record (EHR) de-identified data from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. Each site will provide de-identified data from their health system EHR on a monthly basis that includes all patients identified as having COVID-19 at some point in the interval from February 1, 2020, through December 31, 2020.

NCT04506528
Conditions
  1. Covid19
  2. Cancer
  3. Nicotine Dependence
  4. Pulmonary Disease
  5. Cardiovascular Diseases
  6. Immunosuppression Disorders
MeSH:Cardiovascular Diseases Tobacco Use Disorder
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Death resulting from COVID-19 illness in inpatients vs discharge from hospital (binary outcome)

Measure: Mortality due to COVID-19

Time: February 1, 2020, through December 31, 2020

Description: COVID-19 severity as measured by intubation for respiratory support (i.e., patient required intubation during hospitalization) - binary variable

Measure: COVID-19 Severity

Time: February 1, 2020, through December 31, 2020
26 A Survey to Assess Effects of the Covid-19 Pandemic on Symptomatology, Treatment and Medical Care for Cardiovascular Patients

The design included 152 patients with confirmed heart failure (HF) evaluated in two different periods of time: a baseline before the outbreak, and other during the outbreak of which 76 patients were randomized in each group. A care and follow-up guide was used as an instrument through a face-to-face survey (baseline group) and telemedicine (group outbreak). The primary outcome was the comparison of functional class modification observed in patients

NCT04508920
Conditions
  1. Cardiovascular Diseases
  2. Heart Failure
Interventions
  1. Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: NYHA class modification in the last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). NYHA Scale: Minimum: 1 to maximum :4

Measure: NYHA class deterioration

Time: 1 year

Secondary Outcomes

Description: physiological parameter to worsening of shortness of breath perception, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021).Dichotomic scale presence or absence

Measure: Dyspnea deterioration

Time: 1 year

Description: Physiological parameter to worsening of dyspnea that suddenly occurs to decubitus, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

Measure: Paroxysmal nocturnal dyspnea deterioration

Time: 1 year

Description: Physiological parameter to worsening of quantification of swollen ankles in both pelvic limbs, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence

Measure: Edema

Time: 1 year

Description: a perceived limitation on walking more 500 meters, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

Measure: Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration

Time: 1 year
27 Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial

Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases may increase the ability of COVID-19 to infect cells. The RAAS-COVID-19 trial aims to assess whether temporarily holding these CV drugs in patients who are admitted with COVID-19, versus continuing them, in patients admitted with COVID-19 can impact short term outcomes.

NCT04508985
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
Interventions
  1. Other: Temporarily holding the RAAS inhibitor [intervention]
  2. Other: RAAS inhibitor [continued standard of care]
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The primary end point is a global rank score which is applied to all participants. The global rank sum is based on the following endpoints (and corresponding score): Death (7); Transfer to ICU for Invasive ventilation (6); Transfer to ICU for other indication (5); Non-fatal MACE (Any of the following - MI, Stroke, Acute HF, new onset Afib) (4); Length of stay > 4 days (3); Development of acute kidney injury (>40% decline in eGFR or doubling of serum Cr) (2); Urgent intravenous treatment for high blood pressure/hypertensive crisis (2); >30% Increase in baseline high sensitivity troponin (1); >30% increase in baseline BNP (1); Increase in baseline CRP to 48 hours >30%(1); Lymphocyte count drop >30% (1). The primary endpoint will be assessed from baseline to day 7 (or day of discharge if occurs before day 7). Participants will receive a weighted score depending on the events experienced. The global rank sum score will then be averaged and compared between treatment arms.

Measure: Global rank score

Time: Baseline - day 7
28 Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff

Patients are part of a family network. When any person in a family becomes critically unwell and requires the assistance of an Intensive Care Unit (ICU), this has an impact on all members of that family. COVID-19 changed visiting for all patients in hospitals across Scotland. It is not known what effect these restrictions will have on patients' recovery, nor do we understand the impact it may have on their relatives or staff caring for them. This study will look at the implications of the visiting restrictions as a consequence of the COVID-19 pandemic upon patients without COVID-19 who are in the cardiothoracic ICU. It will also explore the impact of these restrictions on them, their relatives and staff. This study will be carried out within a single specialised intensive care unit in Scotland using mixed methods. The first arm of this study will use retrospective data that is routinely collected in normal clinical practice. The investigators will compare patient outcomes prior to COVID-19 with outcomes following the implementation of COVID-19 visiting restrictions. The aim is to establish if the restrictions on visiting has an impact on the duration of delirium. Delirium is an acute mental confusion and is associated with longer hospital stays and worse outcomes in this patient group. The second arm of this study involves semi-structured interviews with patients, relatives and staff that will allow deeper exploration of the issues around current visiting policy. The interviews will last approximately 1 hour and will address these issues. They will then be transcribed word for word and analysed using grounded theory, meaning the theories will develop from the data as it is analysed.

NCT04538469
Conditions
  1. Cardiovascular Diseases
  2. Delirium
  3. Critical Illness
  4. Intensive Care Unit Delirium
  5. Thoracic Diseases
  6. Respiratory Failure
  7. Cardiac Disease
  8. Cardiac Failure
Interventions
  1. Other: COVID visitation restrictions
MeSH:Respiratory Insufficiency Thoracic Diseases Delirium Cardiovascular Diseases Heart Diseases Heart Failure Critical Illness
HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Congestive heart failure Right ventricular failure

Primary Outcomes

Description: Number of days patient found to have delirium using the Confusion Assessment Method for the ICU (CAM-ICU)

Measure: Duration of delirium

Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

Secondary Outcomes

Description: CAM-ICU

Measure: Incidence of delirium

Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of critical care stay

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of hospital stay

Time: From the date of admission to the hospital until discharge from the hospital or death, whichever came first, up to 12 months.

Measure: Doses of specified drugs during ICU admission

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of time ventilated

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Measure: Mortality

Time: 6 months

Other Outcomes

Description: Semi structured interviews

Measure: Exploring the experiences of patients, relatives and staff of the visitation restrictions during the COVID-19 pandemic

Time: 18 months
29 Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial

The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in older COVID-19 patients who are at high-risk for cardiovascular disease. The purpose of this study is to determine if renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or death. We would also like to determine if there are differences between ACEi and ARB therapeutic treatments.

NCT04591210
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
Interventions
  1. Drug: Angiotensin converting enzyme inhibitor
  2. Drug: Angiotensin II Receptor Blockers
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Within first 28 days post randomization

Measure: Death

Time: 28 days

Description: Within first 28 days post randomization

Measure: Mechanical ventilation

Time: 28 days

Description: Within first 28 days post randomization

Measure: ICU admission

Time: 28 days

Description: Within first 28 days post randomization

Measure: Major Adverse Cardiac Events (MACE)

Time: 28 days

Secondary Outcomes

Measure: Days alive and out of hospital

Time: 30 days

Measure: Days alive and out of hospital

Time: 180 days

Measure: Cardiovascular mortality

Time: 1 year

Measure: All cause hospitalization

Time: 1 year

Measure: Percent of patients require intensive care

Time: 1 year

Measure: Percent of patients requiring ventilation

Time: 1 year

Measure: Percent of patients requiring dialysis

Time: 1 year
30 Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia

The CVP-COVID19 registry is both a retrospective and prospective study design in order to identify predictors of cardiovascular disease progression and mortality for COVID-19. The registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2 admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The study does not test any new diagnostic or therapeutic approach. Patients are treated according to good clinical practice. Patients characteristics, including medical history (with particular attention to cardiovascular and pneumological risk factors), features of physical examination, results laboratory and radiological tests and treatments (pre- and in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate and propensity) are performed in order to identify factors associated with disease progression. Primary endpoint: mortality.

NCT04606732
Conditions
  1. Covid19
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: All causes mortality

Measure: Mortality

Time: 30 days

Description: All causes mortality

Measure: Mortality

Time: 6 months

Description: All causes mortality

Measure: Mortality

Time: 1 year
31 Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

This study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (EMR) of a large representative sample of patients under investigation for SARSCOV2. The objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. An additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protects individual privacy but promotes rapid dissemination and implementation of knowledge.

NCT04610515
Conditions
  1. Covid19
  2. ME/CFS
  3. SARS COV2
  4. Novel Coronavirus Infection
  5. Neurocognitive Disorders
  6. Cardiovascular Diseases
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Cardiovascular Diseases Neurocognitive Disorders
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: determine the risk of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in those with symptoms of SARSCOV2 infection with vs. without a positive confirmatory test.

Measure: Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Time: 18 months post enrollment

Secondary Outcomes

Description: Count of ambulatory care and/or ED visits post enrollment as obtained from the EMR

Measure: Ambulatory care and/or ED visits post enrollment

Time: 18 months post enrollment

Description: Count of hospitalizations post enrollment as obtained from the EMR

Measure: Hospitalizations post enrollment

Time: 18 months post enrollment

Description: death during hospital admission as determined by data from the EMR

Measure: Death during hospital admission

Time: 18 months post enrollment

Description: Hospital-free survival as determined by data from the EMR

Measure: Hospital-free survival

Time: 18 months post enrollment

Description: ICU-free survival as determined by data from the EMR

Measure: ICU-free survival

Time: 18 months post enrollment
32 Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial

Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

NCT04615949
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
  3. Cardiovascular Risk Factor
Interventions
  1. Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC
  2. Drug: Placebo
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: proportions of patients not surviving

Measure: All-cause mortality

Time: 28 days post randomization

Description: Proportions of patients needing ICU admission and/or ventilatory support

Measure: Requirement for ICU admission and/or ventilatory support

Time: 28 days post randomization

Description: HF, AMI, myocarditis, new sustained arrhythmia or stroke

Measure: CV complications

Time: 28 days
33 Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19 (Rilevanza Clinica e Prognostica Del Coinvolgimento Cardiovascolare Nei Pazienti Affetti da COVID-19)

COVID-19 infection has been associated with numerous cardiac manifestations. Indeed, SARS-CoV-2 may impact on cardiovascular system through a direct myocardial infection or a secondary cardiac involvement due to hypoxia or metabolic supply-demand imbalance or prothrombotic inflammatory state. As a consequence of and besides acute myocardial damages, COVID-19 could also determine chronic cardiovascular consequences, with a significant impact on long-term prognosis, quality of life and functional capacity of COVID-19 survivors. On this basis, we aim to define the clinical and prognostic effects of myocardial involvement in COVID-19 patients.

NCT04624503
Conditions
  1. Covid19
  2. Myocardial Injury
  3. Cardiovascular Diseases
  4. Heart Failure
  5. Cardiovascular Morbidity
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Mortality due to cardiovascular causes at 1 month after hospitalization

Measure: Cardiovascular mortality

Time: 1 month

Description: Mortality due to cardiovascular causes at 6 months after hospitalization

Measure: Cardiovascular mortality

Time: 6 months

Description: Mortality due to all causes at 1 month after hospitalization

Measure: All-cause mortality

Time: 1 month

Description: Mortality due to all causes at 6 months after hospitalization

Measure: All-cause mortality

Time: 6 months

Description: Major adverse cardiovascular events at 1 month after hospitalization

Measure: Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)

Time: 1 month

Description: Major adverse cardiovascular events at 6 months after hospitalization

Measure: Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality)

Time: 6 months

Secondary Outcomes

Description: NYHA functional class: from I (no limitation of physical activity) to IV (severe limitation with symptoms at rest)

Measure: NYHA class

Time: 6 months

Description: Left ventricular systolic function evaluated with multimodality imaging

Measure: Left ventricular systolic function (cardiac magnetic resonance, echocardiography)

Time: 6 months
34 The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the COVID-19 Uninfected Jordanian People

The Renin-Angiotensin-Aldosterone System (RAAS) is involved in blood pressure regulation and electrolyte balance. Angiotensin-converting enzyme (ACE) is a critical regulator of RAAS by cleaving angiotensin (Ang1) to Angiotensin2 (Ang2), which is the most powerful biologically active product of RAAS [1]. In the same context, angiotensin-converting enzyme 2 (ACE2) converts Ang2 to Ang (1-7), which is a vasodilator, antithrombotic, and antihypertrophic peptide [2]. ACE2 which is found in many tissues [3] has opposite effects to ACE on the heart, kidneys, and lungs [4]. Many pathological conditions, in particular cardiovascular disease (CVD), have shown a link between a disturbance in ACE/ACE2 ratio and the downregulation of ACE2 levels [5]. Also, ACE/ACE2 has been reported to be higher in moderate to severe chronic heart failure [6] as well as systolic blood pressure [7]. Recently, an elevated ACE/ACE2 ratio is linked to Coronavirus disease 2019 (COVID-19). SARS-COV2 enters target cells by binding of the spike protein to ACE2 and a specific transmembrane serine protease 2 (TMPRSS2) for the spike (S) protein priming, which also leads to downregulation of ACE2 [8]. Down-regulation of ACE2 caused by Coronavirus may have a potential role in the pathogenesis of COVID-19 infection. Accordingly, people with a higher ACE/ACE2 ratio may be more at increased risk of worse Covid-19 consequences [9]. On the other hand, omega-3 fatty acids could decrease CVD risk by their anti-inflammatory anti-thrombotic function [10]. A meta-analysis comprising 15,806 patients, showed that omega-3 fatty acids associated with a 30% reduction in fatal myocardial infarction and sudden death, in addition to a 20% reduction in overall mortality [11]. To the best of our knowledge, no clinical trials have evaluated the effect of omega-3 supplementation on serum ACE/ACE2 ratio which is recently ascribed as a potential key in 2019 Covid-19 as well as CVD [5,9].

NCT04658433
Conditions
  1. Cardiovascular Risk Factor
  2. Covid19
Interventions
  1. Dietary Supplement: 300 mg of omega3-FA
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Angiotensin converting enzyme levels pg/mL

Measure: serum ACE levels

Time: 10 weeks

Description: Angiotensin converting enzyme-2 levels

Measure: serum ACE2 levels

Time: 10 weeks

Secondary Outcomes

Description: TC,LDL,HDL,TG

Measure: Lipid profile mg/dL

Time: 10 weeks
35 The Cognitive and spOrt Virtual EPIC Training Study: Investigating the Effects of Home-based Exercise and Cognitive Training in Cardiovascular Diseases

COVEPICARDIO trial is designed to document the effects of remote monitoring of physical exercise and home-based cognitive training on cognitive and physical functions in older adults with cardiovascular diseases.

NCT04661189
Conditions
  1. Cardiovascular Diseases
Interventions
  1. Behavioral: Physical exercise training
  2. Behavioral: Cognitive training
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Validated remote version of Montreal Cognitive Assessment

Measure: Change in general cognitive functioning

Time: Baseline and post-intervention at 6 months

Description: Validated remote version of Rey auditory verbal learning test, Trail Making Test, as well as Phonological and Semantic Fluency, Similarity, and Digit Span neuropsychological tests and iPad tests (Composite Z-score).

Measure: Change in executive functions

Time: Baseline and post-intervention at 6 months.

Description: Validated remote version of Rey auditory verbal learning test, Trail Making Test, as well as Phonological and Semantic Fluency, Similarity, and Digit Span neuropsychological tests and iPad tests (Composite Z-score).

Measure: Change in processing speed

Time: Baseline and post-intervention at 6 months

Description: Validated remote version of Rey auditory verbal learning test, Trail Making Test, as well as Phonological and Semantic Fluency, Similarity, and Digit Span neuropsychological tests and iPad tests (Composite Z-score).

Measure: Change in episodic memory

Time: Baseline and post-intervention at 6 months

Secondary Outcomes

Description: 4-meter walking test (m/s).

Measure: Change in Walking speed

Time: Baseline and post-intervention at 6 months.

Description: Timed up and Go test (s).

Measure: Change in Functional mobility

Time: Baseline and post-intervention at 6 months

Description: Timed one-leg standing test (s)

Measure: Change in Balance performance

Time: Baseline and post-intervention at 6 months

Description: Timed Sit-to-Stand test (s).

Measure: Change in Lower limb muscles strength

Time: Baseline and post-intervention at 6 months

Description: Matthews cardiorespiratory fitness questionnaire (the score is an estimation of individual VO2 max (ml.kg.min) and range from 15-50, with a higher score indicating a higher VO2max)

Measure: Change in Cardiorespiratory fitness

Time: Baseline and post-intervention at 6 months

Other Outcomes

Description: 36-Item Short Form Health Survey (Scale ranges from 0-100, with a higher score indicating a better health status).

Measure: Change in Quality-of-life

Time: Baseline and post-intervention at 6 months.

Description: Geriatric Depression Scale questionnaire (Score ranges from 0-30, with a higher score indicating larger depressive symptomatology).

Measure: Change in Depressive symptomatology

Time: Baseline and post-intervention at 6 months.

Description: State-Trait Anxiety Inventory questionnaire (Score ranges from 20-80, with a higher score indicating higher anxiety)

Measure: Change in Anxiety

Time: Baseline and post-intervention at 6 months.

Description: Perceived Stress Scale questionnaire (Score ranges from 0-4, with 0 no stress,1 mild stress, 3 moderate stress and 4 severe)

Measure: Change in Perceived stress

Time: Baseline and post-intervention at 6 months.

Description: Perseverative thinking questionnaire (Score ranges from 0-60, with a higher score indicating more repetitive negative thinking)

Measure: Change in Repetitive negative thinking

Time: Baseline and post-intervention at 6 months.

Description: Connor-Davidson Resilience Scale 10 questionnaire (Score ranges from 0-40, with a higher indicating better the resilience)

Measure: Change in Self-perceived resilience

Time: Baseline and post-intervention at 6 months.

Description: Lubben Social Network Scale questionnaire (Score ranges from 0-30, with a higher score indicating more social engagement).

Measure: Change in Perceived social support

Time: Baseline and post-intervention at 6 months.

Description: Social and community involvement questionnaire (Score ranges from 0-200, with a higher score indicating more social and community involvement).

Measure: Change in Social and community activities involvement

Time: Baseline and post-intervention at 6 months.

Description: Physical Activity Scale for the Elderly questionnaire (Score ranges from 0-400, with a higher score indicating better level of physical activity).

Measure: Change in Self-reported physical activity

Time: Baseline and post-intervention at 6 months.

Description: Pittsburg Sleep Quality Index questionnaire (Score ranges from 0-21, with a higher score indicating worse sleep quality)

Measure: Change in Sleep quality

Time: Baseline and post-intervention at 6 months.

Description: Berlin Questionnaire (Participants are classified into High Risk or Low Risk based on their responses to the individual items and their overall scores in the symptom categories.High Risk: if there are 2 or more categories where the score is positive. Low Risk: if there is only 1 or no categories where the score is positive).

Measure: Change in Risk of sleep apnea

Time: Baseline and post-intervention at 6 months.

Description: Short Diet Questionnaire (Score ranges from 15-45 points, with a score between 15-29 categorised as unhealthy, 30-37 as somewhat unhealthy, and 38 or more as a healthy diet).

Measure: Dietary patterns

Time: Baseline

Description: Intolerance of Uncertainty scale questionnaire (Score ranges from 27-135, with a higher score indicating higher intolerance of uncertainty).

Measure: Intolerance of Uncertainty

Time: Baseline

Description: Anxiety Sensitivity Index questionnaire (Score ranges from 0-64, with a higher score indicating a higher sensitivity to anxiety)

Measure: Anxiety Sensitivity

Time: Baseline

Description: Perceived vulnerability to disease questionnaire (Score ranges from 15-95, with a higher score indicating a higher perceived vulnerability to disease).

Measure: Perceived vulnerability to disease

Time: Baseline

Description: Rami and colleagues' cognitive reserve questionnaire (Scale ranges from 0-26, with a higher score indicating a greater cognitive reserve).

Measure: Cognitive Reserve

Time: Baseline

Description: Short Form Bem Sex-Role Inventory questionnaire (30 items questionnaire with 10 items assessing the femininity traits, 10 items assessing the masculinity traits, and 10 items neutral, not scored. Two scores are calculated for femininity and masculinity, respectively, and range from 10-70, whit a higher score indicating a higher femininity or masculinity trait).

Measure: Self-reported masculinity and femininity traits

Time: Baseline

HPO Nodes


HP:0001626: Abnormality of the cardiovascular system
Genes 4425
MERTK SLC25A26 TRNK MTHFR ALDH18A1 SCN9A B3GLCT GNPTAB MITF GJB4 NDUFS4 MEGF8 SCYL1 TREX1 SLFN14 LMNA DOLK SDHA RANGRF SCNN1G CD247 EFTUD2 KRT16 SLC25A4 NTRK1 ATP6V1A CTNND2 ARVCF SIX3 ND1 WDR11 ANTXR1 CTSB NBEAL2 RREB1 TOPORS NOS1AP RRM2B CAV3 LETM1 GNA11 KIF3B IFT172 NPHP3 COG4 ELMO2 ANTXR1 PEX11B DNAH11 KRT2 APOB RPS6KA3 PRKAG2 GJB6 CDSN ZAP70 HRAS ZIC3 NKX2-5 BUB1B FLRT3 NXN RAF1 NKX2-6 KCTD1 TTC7A SPATA5 DNAH1 BRIP1 FGA SGO1 VPS13B TKFC CRYAB CNBP SEC24C CDK8 TULP1 MYH6 B3GALT6 TWNK PLEC SLC37A4 PIGA TSC1 ATRX FOXF1 FOXC1 WAC GNS TERC MPL THSD1 EVC2 DLST CRB2 FLNB ATP6V0A2 TPM2 AK2 ACTN4 SPAG1 RTL1 ITGA8 EFEMP2 C8ORF37 IL7 KRAS ECE1 XYLT1 VPS45 SLC25A24 POMT2 TPM2 CCR6 KCNE1 PLAGL1 AHI1 SNTA1 PALB2 FOXP1 KDSR RELN CAV1 ARL3 MYF6 IGF2 COL3A1 CBL ATP6V1E1 COL5A1 ACD PPP1R15B ACVRL1 AMMECR1 HNF4A ADA2 CDKN2B ERCC8 SBDS SOX3 FANCL NDUFB11 CPLX1 PRKAR1A LYST PRPH2 SLC18A2 RINT1 COX10 SLC2A1 VPS33A LDB3 XK TTN NKX2-5 GJA1 NGLY1 GLI2 ODAD4 MYH11 MAF FLI1 SMG9 SDHA AGPAT2 CAV1 MKS1 TAF2 LRRC6 COL11A2 HOXA13 CASK CCBE1 SMPD1 BTD KCNMB1 TDGF1 PIK3CA WDPCP LACC1 KCNJ2 ND4 RPS19 CHRNA7 IGF2 KAT6A AIRE DISP1 MYD88 DHDDS GNAI3 DOCK6 KRAS IRF8 ERMARD BAP1 APP RPE65 SLURP1 CALR FN1 SLC19A3 ALX4 TSPYL1 PEX13 SLC39A4 NDUFB11 TTN FOXC1 RBCK1 HNRNPA2B1 TRPM4 ZIC2 WDFY3 KYNU PSMB9 CD2AP APOE SMAD4 ITGB3 TRNK KCNQ1 SNX10 KCNJ2 HMBS FKBP14 FGF8 BRAF SC5D SHH ALOXE3 FAS SCARB2 HACD1 CREBBP CITED2 MMP2 HADH NEXN NODAL ABCC6 PORCN CEP57 PIK3R2 RAD21 SCYL1 VCP KCNE2 USH2A TCTN3 PTPN22 ESR1 TRNS2 CDON TIMMDC1 C1R STRA6 IL10 DLD SCNN1A DNM2 SOS1 CDKN1C TGM1 TNNC1 LPIN2 CCN2 MAP3K7 HLA-DRB1 FRG1 TSC2 PPP2R5D GLI2 SLC2A1 EYS FDFT1 IFNG ANK1 SYNE2 ARL6 IRF6 TAB2 PCSK9 TP63 CARS1 HABP2 MYSM1 ERGIC1 ALOX12B DYNC2H1 DSG1 NSUN2 FLT4 FERMT1 DNAL1 CRYAB PPARG GNB5 TRNE TSFM MEIS2 DYNC2LI1 TRNL1 NT5E EWSR1 POU6F2 CSGALNACT1 ELN PRCD FBN2 KAT6B PLCG2 THBD PEX5 SLC2A10 SPOP GBA CYP17A1 SHANK3 SGCG TRNK PNP ACTA1 AGTR1 FERMT1 SIM1 GNA11 DGCR2 NCF4 ODAD2 FMR1 CYTB HCCS GBA SNIP1 DNAI1 LMNA PSMD12 NBEAL2 MKKS LMNA WAS DMD NDUFA10 ITGA3 HESX1 PIGL SDHAF1 POMK MKS1 CYP11B2 ATAD3A IL2RB CACNA1S GLI2 RNU4ATAC NEU1 TASP1 PMS1 RNASEH2A FAH BRCA2 ODAD3 FKTN FHL1 IL17RA C2CD3 CALM2 MCTP2 PDE11A IGLL1 ODAD3 ATN1 TPM3 MYOT SMOC1 PUF60 SOX10 RYR1 NDUFAF6 TRIP4 IQSEC2 GATB ADAM17 SDHB GLMN LRRC32 TMEM216 NLRP3 CISD2 BAP1 MED12 CYBB COL1A1 STAC3 BSCL2 PTPRC VWF CHST3 FOXH1 NDUFA2 TNNI3 YWHAE SNX10 COX3 COG8 LRRK2 FBP1 TMTC3 GNPTAB CTSK TREX1 XPR1 HADHB ZFPM2 SCNN1A PCARE STRA6 NDUFAF2 IL17RD RBM20 FANCB GLI2 CLCNKB CCDC141 RPGRIP1L PHKG2 F7 RPL10 COL4A1 WDR26 HMBS EGFR ABCC8 PLAGL1 BCR NDUFAF2 CCDC22 SAMD9 DMPK ERCC5 SCN5A USP18 HYMAI C1QBP PRRX1 SLC29A3 ARMC5 PLAG1 COLGALT1 KAT6B MEFV DNAAF2 ITGA2B KDM3B GJB2 NFKB1 IL1RN EED IRAK1 FHL1 TGFBR1 REN ABCB4 COL4A2 MDH2 CALM1 UBE2A SP110 PIK3CD SRD5A3 ENG MAX ATP6 NSDHL HSPA9 PROK2 SETD2 CTLA4 SMARCD1 SOX2 ND5 PQBP1 TELO2 F10 DZIP1L JAG1 GATA6 JAM2 MYH7 KRT14 ALB PEX5 TTC8 ADA2 BPGM RIPK4 FRG1 CIB1 KCNH2 CHCHD2 TSR2 POLR1A WNT5A TET2 RGR SOX9 TGFB3 TMEM67 BMP2 CEP41 GYPC ZNF462 GPC4 FBN1 DDRGK1 COX6B1 RBM10 CFAP410 FGFR2 GDF6 TF MAP3K1 ATP2C1 BMPR1A BBS12 DPM1 MDM2 PARN RHOH NFKB2 RFWD3 VHL H19 TBX1 LIAS MOG TLL1 PPARG DCLRE1C NAXD ABL1 CFHR1 SELENOI GNAS NRL KCNE3 NHP2 CYP11B2 TGFBR3 KRAS NTNG1 OSTM1 SLC17A5 SDHB ABCG8 COL5A2 NODAL F13B SDHC TNFRSF11B IVD F9 IRX5 GDF2 PSMB4 PCNA PIGU SAMHD1 NXN DSP ANTXR1 UBR1 FGFR2 PEX6 NKX2-5 COL3A1 TRNL1 ARHGAP31 MS4A1 NODAL USB1 BBIP1 F13B CASP8 CAVIN1 CYP11B2 ASXL1 IFNG FGFR1 ARX PLAU PROC RLIM DTNBP1 ZNF408 SFTPA1 TRNS2 ITPA JAK3 BMP2 BAP1 NBAS FZD2 ATP6V1E1 BTK ATM CACNA1S HADHA MCIDAS NOS3 NODAL PTEN ZMYND10 NFIA ACTA1 PSAT1 SYNE1 BCOR ABCC9 CYLD CD81 COL3A1 GJA8 FGF8 RPGR SCN3B COX3 RPGRIP1 CPLANE1 CYBC1 FANCD2 FGFR2 RAG1 CRLF1 SMARCA2 NPHP1 MYT1L ACE CLEC7A GLI3 CYP27A1 FRAS1 NFU1 PMM2 PAFAH1B1 ZMPSTE24 CEP41 DLL1 FERMT3 CCNQ PTEN EYA4 NPHP1 KCNN4 PRDM5 HFE MPL SIK3 SLC40A1 TERC RPL27 SEC23B TRPV3 PPOX TCF3 SUMF1 SDHAF1 COL1A1 STAT5B SUFU CREBBP SOX9 STK36 BBS4 SLC7A7 GJA1 ADD1 DOCK6 CD46 DIS3L2 MFAP5 KNSTRN ARX TNNT2 SF3B1 KMT2E INPP5E BANF1 GYG1 ARHGAP31 ZFPM2 RMND1 ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 XYLT1 ERF PEX19 ENPP1 MED25 NCAPG2 FOXH1 HJV SEMA3E AIP IKBKG IQCB1 MRPL3 SP110 NAGA MED13 LIG4 NDP HPSE2 TRPM4 FZD4 FLNB FCGR2B LHX4 INPP5E KATNIP TRIP11 TTC8 PSAP TREX1 ND2 ND5 IDH2 BRCA1 RPS6KA3 FHL1 USP8 SLC25A11 MASP1 LMNA LMNA WDR37 TRPM4 PEX3 TRNF OTC FADD OTC TMEM126A MTAP PPARG TRNQ KIAA0586 ZMPSTE24 RAI1 ELN KPTN LBR KDM6B SON AGXT TRNS1 PDCD10 CYP7B1 TRDN DMXL2 SPATA7 NPHP3 TRAPPC11 ELN PTCH2 MAP1B TGFB2 ARHGEF18 JAK2 SUMF1 GUSB ADCY5 IFNGR1 DHCR7 GUSB KITLG HADHB BVES C12ORF57 SDHB GBA MPIG6B FOXP3 RAC2 STIM1 KRT83 RPL35A AKT1 MYH6 ZFPM2 GJB6 CHST3 KANSL1 PURA SATB2 PITX2 COL4A1 FN1 GLRX5 ADAMTS10 CDK4 AFF4 ZFP57 ERCC1 SCARF2 PCNT PRPF8 NPHP4 LRRC8A RPL26 RMRP ACTG1 TTN OTUD6B KDM6A ECHS1 KCNQ1 ATP5F1E CTCF TGDS CNGB3 TMEM107 GAS8 POLG DNAAF2 SCNN1A ACTA1 MTM1 FLNA POMP HABP2 MTTP TRNL1 FGFR1 TGFBR2 FKRP OTX2 PTPN22 CFI LRP2 PHF21A ZIC2 EOGT RNF6 PLIN1 INSR WRN KRT5 PIGN NDUFA10 FKBP14 WWOX PPA2 LDLR GATA4 GATA6 TBX1 ENG POLH NSMF ARID1A KCNK3 NSD1 F5 KCNN3 REEP6 NKX2-5 CREBBP KIT ZFPM2 CDH23 PDE6D ATP6V1A TMEM231 MTFMT PROS1 XYLT2 EPCAM KCNQ1 P2RY12 IL10 PDGFRB SLC4A1 LRP6 NDUFS8 GCK SDHD DCAF8 STRADA PNPLA2 NDUFB11 DDRGK1 FUCA1 RNASEH1 RNASEH2C ND4 NF1 AKAP9 NOTCH3 FLNC DNAAF5 PEX5 PDHA1 SMARCE1 ERCC4 MYH9 CCDC22 COL1A2 STAT3 CCND1 TMPO ND6 IMPG2 CALM1 CCDC8 TGIF1 NEUROD2 DNAH5 ABCA4 TRAF3IP2 ARFGEF2 TBX1 KISS1R SSR4 ALG8 DDX3X TRNS1 KDSR HAAO RIN2 TUB MKKS RSPO2 DNMT3A ETV6 GNB3 HK1 AFF4 GBA RAB3GAP2 PPCS FGB IL23R DVL1 F8 FBXW11 APOA2 CYBA RAI1 MYH11 CITED2 PEX12 TFAP2B HADH SCN9A FGF8 CASR POLE LOXL1 ICOS FADD AMMECR1 SCN5A LMNA TNNI3 CDON PDE6G SDHD MANBA PIGT TDGF1 DYSF CCDC40 ALMS1 FGA ANO5 PARS2 RPGRIP1L TERT GJB3 CDIN1 KCNE1 FOXH1 SOS1 NRAS CACNA1D WAS CASR DHODH F2 PNPLA2 EHMT1 NF2 TCIRG1 DYRK1A NDUFS1 FAS MYH7 TOP3A SAMHD1 WDR35 NSMCE3 PTEN TGIF1 G6PC1 CCDC28B KRAS GTF2I TNFRSF1A FBN2 TWNK HGSNAT GNAQ PRDM6 APOA1 DSC2 SRD5A3 IFIH1 FTO KCNJ11 GNAS AMER1 SETD5 LIPC COX2 MINPP1 NFIX RNU4ATAC OFD1 RASA1 AIP COL6A3 WDR35 FAS ACVR2B RNF135 CDH2 SFTPA2 MKS1 UPF3B ANTXR2 PRF1 KRT1 AARS2 TSHR TRNT1 SCN5A GATA1 NRAS GREB1L ERAP1 RAB27A SCN10A MC4R PACS1 PRKACA GLI3 LYST GBA GATA4 TKT TBX4 MYMK COL4A4 SCN2B CEP290 KLRC4 SCAPER MMP1 KRT9 F13A1 VIPAS39 PRPF31 PIGN HLA-DRB1 AIPL1 MPL ADAMTS2 TMEM237 CD55 MVK NKX2-1 DLK1 TPI1 APOE GNAO1 WT1 ELANE GTF2E2 PKP2 ABCC9 GPR35 CIITA TRAPPC4 MED12 CDKN1A CLCC1 CRPPA GJB3 MEIS2 RAF1 MIPEP PEX1 COX3 COX7B NEBL SH2B3 ERCC3 ERCC2 KCNAB2 TAB2 CTNS SETX ANGPTL6 CD19 TRIO STK4 POLH ERCC5 GALNS POMT2 NFKBIL1 ADAM17 TET2 NAA10 SF3B1 SLC26A3 GFI1B KMT2D ABCA12 LRP5 UBR1 PEX3 FEZF1 COL7A1 HSPG2 TRPM4 TRNK NDUFAF4 C12ORF57 MYBPC3 GTF2IRD1 CAVIN1 KRAS PIGY VWF TGFBR2 SPINK5 RASA2 APC PHGDH SLC25A24 NGLY1 LARP7 STAG1 RYR2 CCND2 FANCM UCP2 RPL10 CDKN2A DSG2 ANO10 NELFA NLRP3 KCNJ11 PIK3C2A GLI1 CTCF KCNQ1 LRP5 TCF4 CFHR3 POLG TBX5 SHPK HLA-DPA1 TMEM43 SETBP1 LMNA RIT1 SVBP CEP164 AKAP9 ATP6 FKRP CYP27A1 CACNB2 WAS SDHA NF1 LAMB2 BAG3 RARA ACTL6B TREX1 ABCC6 COL11A1 HSPG2 KCND3 CNGA3 IL36RN SLC19A2 CYP1B1 COL3A1 CD96 CYBA ERCC8 TET2 GLIS3 DLD TERT PEX2 FOXH1 SURF1 ATOH7 GFI1B HRAS CASP10 TSC1 TNPO3 NIPBL PITX2 WDR19 GAS1 MYCN TXNRD2 IL10RA ATP7A MYH9 ACTA2 TRNW GDNF CTLA4 PDE4D SPTB ADAMTS3 GLB1 SGCD ERCC3 F7 HLA-B COL5A1 CBS SNCA FGFR2 LIG4 RNU4ATAC CLN3 GNE AKR1D1 ADA2 KCNJ1 FGFR1 CFI ERCC2 DISP1 FKTN ATP6AP2 NLRP3 FGFR2 COQ2 SPECC1L ARL6IP6 FAH ND5 NR0B1 LIG4 MAP3K20 POMT1 FOXE3 PDGFB GYS1 SDHAF2 SLC26A2 FAS PRKAR1A SERPINC1 RLBP1 TCIRG1 CALR PIK3R1 LIFR KCNQ1 SDHD ZNF687 SLC35A2 FGF8 CCDC40 CTLA4 SCN5A HBA2 ARSA DCAF17 CFTR SCNN1G ESCO2 GJB4 ITGA2B KIF1B BEST1 RP2 GATA6 BBS9 ARNT2 KCNJ18 HTRA2 SPRY2 STAT1 GTPBP3 FGF8 SCNN1A SNRPN MYOC GPR101 ATP5MK HNF1A MAX LRIG2 LONP1 PLEC CXCR4 ERCC8 COQ9 PTDSS1 SLMAP STIM1 CCND1 KCNQ1OT1 AHCY ATPAF2 FANCC POLR3A SKIV2L PADI4 CYTB MAF TERT SFTPC FOXJ1 NPC1 AICDA FANCI CALM3 NDUFS2 EDA LDLRAP1 TFAP2B CALM3 PEX6 CFAP298 CSTA SELENON TRIM28 ZIC2 KLHL7 NPC2 TBX22 ALMS1 GPD1L FGF8 ELN SBDS CERKL CYP11A1 KDM6A LAMP2 B9D1 MAFB DTNA NDUFS2 PEX14 LEMD3 GJA1 FGF20 SGCB MMEL1 DNASE1L3 TGFB3 CCDC141 FANCA LIPN FLT4 MYH7 RDH5 SCNN1B FBXW11 MAN2B1 SCN5A LTBP3 PTCH1 MGME1 EPG5 NKX2-5 GAS2L2 PPP1CB F13A1 PDE6H HIC1 CBL CWC27 PDE3A FLNA CHRM3 POLG2 JPH2 IRF5 IL17RC GNAQ SMARCA4 APP PIGM HPS5 TMC8 COL4A5 LYZ NFIX RTEL1 PRKG1 PLN ATAD3A MPI BRAF IFT172 FMR1 ALG14 PAH WRN TGFB1 RBM8A NDUFB9 SFTPA2 CDH23 FGFR3 RET NR2F2 JMJD1C TNNC1 SLC30A10 GLI2 BUB1 GMPPB NRXN1 COQ7 OCLN VCL TMEM237 TFAP2B TBX1 WDR19 RRM2B COX4I2 KAT6B FLNA DNAI1 HCCS NOTCH1 IFT140 FOXA2 MPLKIP PROS1 LZTR1 SOS2 NDUFS2 CACNA1H TPI1 FECH CYP11B1 GNA14 MADD GCDH PEPD MYT1L MYO18B GTPBP3 SDHA IDH1 CDKN2A SCN4B SOX10 FBLN5 YY1AP1 CDKL5 RPS10 TANGO2 NPPA GAA AKAP9 NDUFS2 PIGO MAP3K7 LMNA MEOX1 KRAS TMEM216 RBBP8 KLF1 SCN1B BPTF SMARCB1 SOX10 BRCA2 SPTB ANK2 RNF113A BRAF MBTPS2 RAF1 COL6A1 FASLG TNNT2 CCDC39 DNAJC19 PYCR1 SMN1 EYS TNXB CFH DEAF1 LMNA PSMD12 TK2 INTU ATP6AP1 PEX6 POGZ STAT3 PLG CHRNA1 ACTN2 NEK9 ESCO2 LONP1 TGFBR1 ACAD9 CDH2 POLG TMEM127 LPIN2 KYNU PRDM16 SETBP1 SNRNP200 CFH UVSSA UBE3A MYH7 PRRX1 CPLANE1 TBX20 SFTPC SLX4 CARD9 ARL2BP RECQL4 LEMD3 TNNI3 RPL10 FGFR2 FHL2 GABRD IRF2BP2 EHMT1 NEK10 ABCG5 MYH7 RPL5 CRYAB MKS1 DOCK3 NODAL ABCC9 TFAP2A RPS24 VPS33B RPL35A FGFR2 SGCA RET COQ2 ARL13B IDH3B MGME1 ASAH1 NOTCH2 UBE2T CENPE CHRNG ATRX SNTA1 PRPF3 ERCC6 HBB MED13L KCNQ1 MRE11 JAG1 RECQL4 RPL27 DNAJC19 TDGF1 TALDO1 RNF213 RAI1 HFE NDUFS2 NR2E3 PCARE MAK PHKA2 LAT STXBP1 ZEB2 KDM5B PIGO MAP2K1 PIBF1 PAX6 ERCC4 SOX18 ERBB3 SIX3 ROR2 ND4 BMPR2 CENPF PEX16 PDX1 DUX4 PEX19 FLNA DIS3L2 DLL1 CDON SHH TPM3 CPT2 H19-ICR TBCK MTRR BMPR1A MYL2 HBA2 JAK2 FOXC1 TBL1XR1 GDAP1 RAD51C CACNA1C RRAS2 PRPF6 LIG4 AGK DNAAF6 PIGS RNF125 BIN1 NR3C2 FANCA PRKAR1A GDNF MYPN NOTCH3 IGF2 RUNX1 PRKCD BLNK KRT1 PRPF3 FCGR2C KAT6A FBLN5 ABCC9 GCLC WDPCP IRF5 WT1 LIPA RAB27A KIT TMEM43 ADA AUTS2 CYTB SALL1 SERPING1 CYP24A1 TGIF1 ASCC1 DNAH1 CSRP3 GNE CST3 IGH FAT4 JAK2 PSEN1 G6PD ACADS MYH11 TMEM43 INSR ERCC6 PQBP1 ARID1B ARL3 PDE6A SH2B3 PPOX TP63 SHH PLOD1 AKT1 TTR COPA PEPD SRY SCNN1B FBN1 SNRPB RBP3 GAA CALM2 GATA6 DYNC2I1 CASR ZNF423 RAD51C GALE SDHB HPS3 REST TGFBR2 SCNN1B TAZ PKD1 TPM1 PRKACG HIRA ACTG1 DRC1 SVBP GPC6 GDF1 HOXA1 BAP1 COX1 CSPP1 ELN MGMT ARSB PEX6 RPL11 PET100 RIPK1 CASQ2 ACTB MSX2 ND2 FOXP3 USP9X ND4 SOX4 SLC39A13 PKHD1 CHKB COLQ TTR SPEG RPL11 GLRX5 PAM16 NOTCH2NLC TET2 SCN5A AKT3 PTPN11 MEOX1 RP9 F2 ENPP1 RHO POLR1D TDGF1 TNFRSF13C GLA SELENON HSD17B10 RPL15 TULP1 NF1 ADGRE2 FGB MED13L GATA5 AGL DDC TRMU BACH2 DLX5 ZNF513 IL12RB1 SH2D1A KRAS SLC25A4 SCN5A NDUFA11 GSN CAP2 ALDH18A1 SMAD6 VPS13A EXT2 ITGA2B SLC4A1 FRAS1 NDUFA12 MFAP5 CYSLTR2 CEP55 AGXT FGF17 CLDN1 PDE8B MAGT1 FGFR1 IFNGR1 DES SMAD4 ZNF469 ND1 DOCK8 KMT2D SOS2 SLC19A2 ND5 LAMA4 CTNNA3 FOXRED1 LIPA MICOS13 CSPP1 ACAT1 RORC STING1 DCHS1 GATA3 MEGF8 HLA-DRB1 ZEB2 ARID2 CHN1 PIK3R2 RPL18 STN1 HTRA1 AP1B1 PCCA EXT1 CCND1 CYLD PDGFRA RAC1 KIF15 TBX20 FIG4 SLC20A2 BIN1 LIPA ODAD2 FLNA TRAF3IP1 SMO SLC4A1 PDHA1 DNAH9 TMEM231 GLA SCNN1G NOS3 MBTPS2 EVC NSD2 HS6ST1 DPF2 ITGA2 MAN2B1 PIK3CA LRP5 PKD1 KIF1B APP TNNT2 TNFSF15 PTCH1 LRP5 RBP4 MMP2 LMNA NLRP3 CHD4 LRRC56 FGG ABCC9 CYP11A1 RNASEH2A CIZ1 TNFSF4 ODC1 POLR3A AGPAT2 TWIST1 MMP1 NDUFA4 ND1 IDUA COG4 TP63 PAFAH1B1 PTCH1 PEX7 LCAT COX8A GP9 ABCD3 PRPH2 TP63 DISP1 TCTN2 TNXB SCN1B PPP1CB VANGL1 NR5A1 NKX2-5 TSC2 ACTA2 DGUOK GFI1 MAPK1 IFNG COL1A2 NDUFS3 PHYH MESP2 RPS28 FASTKD2 FOXE3 NLRP3 MRPS16 RAI1 NABP1 SCN9A PCGF2 FLCN DNAJC13 SFTPB ACTC1 PLVAP HBB RPS20 RPSA RAD21 INVS LYST NDUFA11 RARB CD19 BMPR2 DZIP1 APOA1 GATA1 PEX7 NEK2 ATM LMX1B GBA APOE TGFBR2 MYH11 CANT1 RECQL4 HYOU1 IGSF3 TOR1A ATP8B1 CFTR EVC FANCE PARN PRKAR1A TGFB1 MYLK WWOX MTOR RFC2 WDPCP GATA4 RRM2B CCDC103 SETD1A NEB MPLKIP POLA1 FLT1 CD19 CALM1 SIX3 SMPD1 B9D2 SERPINC1 SELENON SPARC HPS4 PTH1R SRCAP ATM MNS1 KRIT1 MYH6 SH3PXD2B GNAT2 CLCN7 TRIP13 HAND2 COL18A1 MST1 ANKS6 RPS6KA3 MEF2A ALDOA FGB FKRP NOP10 AVPR2 COG6 TRNQ BCL11B PRDM16 IVNS1ABP STOX1 ASAH1 ACTL6A NDUFS7 SMAD3 TALDO1 NUBPL CITED2 ERCC2 TAF1A COL4A1 COX15 TEK STEAP3 HADHA ALX4 ACTA1 DSP NDUFB3 EIF4G1 GATAD1 ACTA1 HBB RERE FLNA MAD2L2 CLRN1 LTBP4 PNPLA6 TMEM237 AIP DDX58 POR PGM3 DCC ABCB11 KCNJ8 EOGT VHL PIK3CA MTFMT TEK PLD1 SLC25A4 SDHC DCLRE1C SEC31A TLR4 RSPH3 APOA5 COX7B CYBC1 DCHS1 KCNH1 FANCB BBS2 HBB SRCAP GAS1 TNFRSF13B LMNA CRB1 ZMPSTE24 ANOS1 SMARCE1 KCNQ1 BCOR WARS2 KLHL3 STAT4 SMAD3 GTF2H5 TRNV RUNX1 LRP2 OPA1 PRKAG2 DNAAF4 UBAC2 MAP2K1 RIN2 THOC6 DLEC1 BIRC3 COL4A3 FGA TTC8 SCN1B GATA4 TMEM138 CD27 BMPR1A ALKBH8 CFHR3 MTHFR NSMCE2 VCL MITF QRSL1 DHCR24 CAV1 BNC2 SNAP29 ITK BICC1 RECQL4 THOC6 NAGLU TRMT1 AKT1 JAG1 RERE GDF6 DMD F2 FIP1L1 GJA5 C2CD3 ND5 ATP2C1 APC NFIX NDNF B9D1 ICOS GFM2 SARDH ND6 HLA-B PRKAR1A KCNJ18 MAGEL2 GMPPB NF1 MAP3K7 DLL1 RPS29 NODAL LRBA RDH12 PLP1 RSPH4A TERT FBN1 F5 NAGA RHO ATP6V1B2 RET HSD11B2 WASHC5 TCTN2 DMD GANAB TMEM67 C8ORF37 SLC39A13 CD46 ADAMTSL4 VPS33A DPF2 PIGQ INS SDHA MVK SMARCB1 RPS7 WT1 TRAIP NDUFB11 DNAAF1 TOP3A PRCD CUL7 TCOF1 ALG9 TRNC CALCRL F5 KAT6B POMGNT1 TTN OFD1 EPB41 TERT BRAF CLCN2 APP SLC2A10 RPS15A APP KRT14 GJC2 PTF1A MALT1 HPGD NID1 SOX3 KCNH2 ABCG5 FSHR MAFB DSE GATA6 CFC1 EFTUD2 HBB MYL3 RPL15 PPCS STK11 ALB CDC45 SNAI2 PCNT FOXH1 ESPN TPK1 IDH3A ANKRD11 COL1A2 TARS1 PKLR CEP290 WNK4 CCR6 SH2B3 ALAS2 DNAH9 HSD3B7 PLIN1 BRAF ADNP DSG2 UROS RLBP1 EXT2 TBX1 SMCHD1 PIK3CA TCAP RS1 ATP5F1A GATA6 FANCG SCN5A GP1BA NDUFV2 GMPPA NOTCH1 MAB21L1 ADAMTSL1 AKT2 MCCC2 ND6 DNMT3A SIN3A THPO NOD2 MYH6 WASHC5 CPOX FOXC2 HAMP GJA1 ANKRD26 ACTA2 CYB561 SCN1B PIGT VPS13B PRKCD HYLS1 SUFU PTCH1 DNAJB11 HOXD13 IGF2 TRRAP CFAP300 COL1A2 GDF1 MTO1 IFT27 INTS1 PHKG2 PEX19 MAP2K2 WT1 DLK1 PPP1R17 SMC3 CR2 STX11 F12 MED25 MADD COL6A2 RAB23 SHH ACADVL FAN1 TET2 TKT MYRF HRAS DLL4 F8 MVK CRELD1 GALNT3 SCN5A TPM1 KIAA0753 SCO2 SOX2 ATP8 SLC26A2 PUF60 RYR1 ELP1 AGA BEST1 NLRP3 FANCF VWF FBN1 MMP21 TCIRG1 PNKP F2 CPT1A FLI1 ZIC2 SLC29A3 KIF20A DLL4 IMPDH1 MBTPS2 POLG KRAS SIX3 PEX12 PRKCSH TCTN3 SOX10 SMARCB1 TRNN SCO1 BTK MSH6 KRAS BSCL2 RSPH1 SMAD9 CCBE1 GK DNAH11 AGTR1 ATR CSF2RA NADSYN1 UMPS CDC42 GJA1 LAMA2 SMAD4 SACS TCOF1 NTRK1 DES POMT2 SLC22A5 MCFD2 MYBPC3 XPNPEP3 NOTCH2 SKI SEC23A TTN LORICRIN MRPS14 SYT1 ODAD4 ECHS1 IDUA CACNB2 DLL1 ND1 RNF113A TBX6 RERE FLNA CASK DGCR6 TTC7A SFTPC RAG1 UROS INTU CKAP2L EDNRB NLRP1 IFT81 ABCD4 EPHX2 COG4 EED SIK1 ETHE1 RPS19 IL12A-AS1 ENG CDKN1B HLA-DRB1 HYLS1 NPM1 NDUFS4 MC1R SCN11A TACO1 RB1 CTLA4 PRG4 CEP19 KLF1 C1S CRELD1 PHYH DSE PEX1 ERBB3 RPGR TCF20 LIMS2 GUCY1A1 GALC TUBB RET JUP NLRP3 ALDH3A2 DHX38 IFT80 FGFR3 FXN FGA MKS1 SEMA3A HBA2 NPHP3 WFS1 VHL PMM2 COL4A3 BRAF ABCB6 IDUA MNX1 PRPH2 RPGRIP1L EYA4 FBN1 HBG2 SLC29A3 CNTNAP2 RAG2 CAPN5 CTSA PGM3 CHRNA7 FANCE MPL COL7A1 NDUFS6 HIBCH FKTN ZEB2 XPA NEK1 GJA1 TRDN FLNC ENG AKAP10 KIAA0586 CCNQ PLN NDP AGA LAMC2 RAG2 IL17F VAMP7 CEP104 FANCC SNCA PYGL CCN2 TPM3 TWNK GGCX COQ2 FOXE3 NCF1 CD3D ABCA4 TAF2 RIT1 MGAT2 SAA1 KIZ IL7R TBC1D24 TTC37 LTBP4 SPTA1 MLX COL1A2 IDH1 SMAD3 TGM5 FOXRED1 PEX16 NOS3 GHR DDX11 HYMAI GDF2 PRKAG2 HLA-DRB1 MRPL44 NDUFA1 DNMT3A NEU1 ATIC EDN3 FLNC CPS1 PRKAR1A APRT GPIHBP1 DNMT3B IDH2 SCN3B PTPN11 EDN1 MECP2 AGK NDUFV2 USF3 ACVRL1 TFR2 FLNA MTTP NRAS OTX2 CC2D2A DNAAF6 FGF23 CLCN7 ANK2 NOTCH1 FBN1 NUP188 NDUFAF3 STAT3 PEX2 PEX10 CARD11 TBX5 BAG3 ERCC6 STX16 SMAD4 SLC25A13 PGM1 LRP1 JAK2 HMGA2 AHI1 RPL31 ELOVL4 AQP2 PIK3CA TP53 CNGA1 BRCA2 PALB2 GAS1 PSAP PTCH1 CFI PTEN STAT3 TMEM67 SCN10A KBTBD13 TREX1 AHI1 ACTC1 JAK2 ISG15 MYH7 ACTG2 BEST1 TMEM126B MAP2K2 ACADM DLL3 RYR1 FUT8 PEX12 ASXL2 KIF11 GP1BB MSL3 HADHA TERF2IP SH3BP2 HNRNPK NFKB2 FREM2 IFT172 HIBCH PIGY ANK1 TGIF1 CAV3 IDS AVPR2 NEK9 SELENON PSTPIP1 CCM2 LEMD3 ATAD3A GATA4 NR3C1 NEUROG3 SCN2B TBX1 POU2AF1 TDGF1 PRKACA ADNP CA4 CD28 CDC73 SIX3 PML BLOC1S3 KCNJ5 CHD7 POLR1C POR TNFRSF11A FH ATRX HES7 FOXC2 NKX2-6 FOS GLB1 CC2D2A DSP MYH3 KRAS HSD3B7 ALDH18A1 ALOX5AP PEX11B SDHD DVL3 SLC12A1 SCNN1A PSEN1 WFS1 GPC3 DCTN1 ALG9 DNAAF5 JUP ZMYND10 CACNA1D IL2RG IL7R PTH1R SMPD1 HLA-A ROR2 GP1BA SMAD4 KDM6A NONO INVS TLL1 RIPPLY2 CLCN7 MYLK NODAL ND6 SERPINA6 GNE BAG3 MEN1 LRRC56 GATA1 TSC2 VPS35 DHCR7 WARS2 NDE1 SLC20A2 WNT10A SLC7A14 GSN RP1 KCNJ5 BMPR1A LBR ARID2 BBS1 SDHD ZNF513 RET CNGB1 KCNJ5 SETD5 NKX2-5 CAV1 ABCG8 DCAF17 DSG2 TF GPD1L AGT GATA1 CTBP1 BTNL2 RYR1 SNX14 CHST3 RAD21 SOX4 SAG ERCC6 TP53 IGF2 BBS10 FUZ SUFU CRTAP PSAP PEX13 GAS1 B3GLCT ABCC6 PLEKHM1 ADAMTS10 ELN RET GATA5 ALDH18A1 CALM2 GATA5 EPB42 GP1BB TCIRG1 DIS3L2 CAV3 TPM2 EMD SCO2 TXNRD2 IKBKG FUCA1 SPAG1 ARID1B GNAS AGGF1 F8 ABCA3 ND4L NLRP12 TGFBR1 NDUFAF5 NOTCH1 PMS2 SEMA5A CAV1 NDUFS8 CD28 CDON GPX4 CA2 CC2D2A PDGFRB GREM1 KIF7 STXBP2 TGM5 ADCY5 EPHB4 ESCO2 FHL1 NEDD4L BCS1L IFT88 CITED2 NDUFB11 BCL2 INPPL1 KRAS CYTB KIT MYBPC3 RPGR CALM1 GRIP1 ATP5F1D FANCD2 PTPN22 FAT4 IFIH1 IL7R LMNA JUP GPC4 FECH H19-ICR SMARCAL1 NAGA GBA CEP290 PDCD10 DISP1 HYDIN SPRY4 MAP2K2 IL2RA FGD1 CDK13 CTC1 PDSS1 PNP PRTN3 ARID1A EPB42 XYLT2 MYH6 FRA16E GP1BB RSPRY1 TRNS1 SDHD BLM CASQ2 CALM3 RRAS SALL4 FANCI LMNA DDR2 ZAP70 ALDOB MNX1 LMNA AIP ND4L C3 IFIH1 TMEM260 NRXN1 USP8 FGFRL1 DPH1 APOE C8ORF37 AP3D1 SALL4 BRCC3 ABCA1 CDK10 KDR TECRL AAAS TBXAS1 C4A MYH7 SH2B1 ERCC6 SBDS DNAI2 NKAP TBC1D24 PEX1 LIPC CHRM3 MTHFR MYL2 TRNE COA6 SERPING1 GATA6 BCL10 PRF1 RAG2 SCN4B GBA GATA4 SMARCA4 GM2A CD40LG KCNQ1 MSH2 TRMT10C MMACHC MIF HES7 GP1BB HLA-DQB1 TRIM32 NKX2-5 GMPPB SLC35A1 AMER1 EIF2AK4 SPP1 XYLT2 KIF7 LBR NCF2 MKKS PTPN22 TMC6 CEP57 FGFR2 DNAI2 SDHA SDHB TRNF TPP2 SDCCAG8 SOX5 PCNA ZNF469 RAG1 CDKN1C CDC73 IFT43 CEP120 HAVCR2 HMGCL KCNJ2 HBB MIB1 SLC4A1 ACP5 XIAP CFAP53 IL2RG ATP7A RNASEH1 FANCB CYP11B1 KAT8 BTK SDHB TTN TMEM231 OFD1 TET3 KLHL7 CDON PTPN11 TXNL4A PHGDH LRP5 FLNA PIEZO1 PIK3CA NNT ABHD5 DVL3 KCNE3 AEBP1 RYR1 CDHR1 HCN4 STRADA PSMD12 CUL3 SLC25A3 ANAPC1 LONP1 ERCC4 FBLN5 ATP6 FBN1 CLRN1 PEX16 FLT4 NIPBL SMAD4 LIPT1 SLCO2A1 NOTCH3 CD109 RPE65 CHD7 SLC37A4 COQ2 TNNT2 SRP54 CD79B SOX18 SGCD TSHR AQP5 TNNT2 CDKN2C MMP14 MED12 TGDS CCDC47 PKD1L1 ND2 ADAT3 CPOX RPS17 APC2 MYH8 TRAF7 KIF7 MYH7 SCNN1A GPD1 DHX37 VEGFC KRT5 TNFRSF1A KIAA0319L CLCN7 YARS2 TBX1 PDE11A SMC1A PIEZO2 TMEM237 NDUFS7 PDGFB TBX1 KCNA5 AKT1 TNFSF12 EFEMP2 PGAP3 ABL1 PIK3CA EHMT1 PDGFRA CTNS SDHD NCF2 NDUFAF5 TNFRSF1B WNT10A FOXP1 PSTPIP1 BCOR TMCO1 GYG1 KDM1A SDHB NDUFS1 NSD2 TECRL F13A1 B3GALT6 CLCNKB TRPS1 BBS1 CSF2RB MPL PERP FAM149B1 COL1A1 HESX1 FCGR2A EDNRA IDS TRIM28 WDPCP CACNA2D1 CD79A PIK3R1 FGFR1 PIGP HNRNPU HPS6 SCNN1G MAP2K1 PDE6A CTSA CPT2 LMAN1 GPR101 SYNE1 TFAP2A COX2 RTL1 CCDC174 COQ2 NR2F2 OFD1 ND6 KCNH2 TSC2 KCNN3 RASGRP1 SP7 GBE1 NDP GATA1 COL3A1 POGZ ENPP1 POMGNT1 SEC23B TCTN3 GLI3 SREBF1 ITGA2B SMARCE1 POU3F4 GIGYF2 SIX6 F11 SEMA3A CDAN1 KIF5A MVK ARMC5 SDHA NDP PTPN14 HAMP CNGA1 PEX26 RYR2 HEXA TP53 HPS1 TET2 COL2A1 FBN1 SCN2A DMD GATA4 FMR1 NKX2-5 ELOVL4 DMRT3 FBLN5 GUCA1B NEK8 TMEM127 CLPB LDB3 RNASEH2C TWNK TBX20 CCR1 HADHA POR WNT4 ELAC2 MEG3 GP1BA TRDN SKI NEXN RAD51 DUSP6 OTUD6B USH2A NDUFA9 MMUT HYLS1 NPHP1 HBA1 CHRND PKP2 PDE6C XRCC2 FSCN2 VHL CCDC103 ERCC6 ZDHHC9 FARSB ODAD1 CYP11B1 ANK1 JAK2 NME8 AHR VHL SLC25A22 LETM1 SLC25A3 ELANE RFWD3 XPA GPC4 ITGA8 GNAQ CDKN1B GNAS ERCC8 C4A DYRK1B TRPC6 DNASE1 CA2 PROKR2 MLXIPL LZTR1 STX3 ALG12 AK2 IDH2 SLC52A2 PDE3A HELLPAR HSD3B2 GP9 SGSH BAZ1B ALG1 WT1 TANGO2 MID1 GP1BA XPC LDB3 NR2F2 DNAL1 TGFB3 SGCB CTSH CTSB DISP1 PRKAR1A TRNL1 UBE3B LCAT MAT2A FIBP CYP11B2 TNFSF11 DSP PET100 LMNA ABCA4 KCNA1 NFE2L2 EPHB2 SGCG PROC IARS2 KCND3 D2HGDH MGP TRDN NHLRC2 SOX9 PGAP2 NAGA PUF60 FKRP CTNNB1 SDHD KCNE2 RSPH9 NOTCH2 PACS1 GNAI2 NAA10 GNB5 GGCX KRT10 CD70 ND1 PIK3CD FMO3 ASS1 EXT1 USP9X PSAP GUCY1A1 LMNA WT1 PIEZO2 GJA5 STN1 DCX KCNE5 GPC1 PROKR2 EBP GNPTAB NLRP3 CFAP221 COA5 JUP GJB2 TP63 TBX3 AP1S1 HBA1 ROBO4 CERKL RPL26 DES EDA2R OFD1 CD81 TNFRSF13B POLG2 FIG4 DDX59 MYH7 NSD1 MTHFR HLA-DPB1 AGT RYR1 CFHR1 BRF1 SLC22A4 SLC25A20 MAPRE2 AKT1 RRAS2 EPHB4 MEN1 XRCC4 COX7B HSPG2 CEP290 CCDC115 LTBP2 DLK1 PROP1 SHOC2 FLT4 ACTB DGCR8 FBP1 NEB SLC35A1 EPAS1 COL1A1 MRAP SPECC1L PSEN2 CDH23 BLM PKD2 CDON PKD2 NPHP1 CST3 RAG1 SNRPB PRKG1 USB1 MYOCD GATA4 TMEM70 NDUFAF6 FLNA STAT2 ZNF365 MEFV PYGM RASA1 NEK1 SOX6 NF1 FKTN NF1 CSRP3 RPL35 HCN4 SRY MYOT TDGF1 GATA4 GGCX TAPT1 TMEM216 COX15 SLC4A1 ROM1 PAX8 COX1 MCM4 TINF2 CD40 TOPORS ERCC2 SDHC NAA10 MPL POT1 CR2 COL1A1 FGG FOXE1 NLRC4 TFRC TRIM37 EXT2 LMNA KMT2A ITGB3 TBX3 STXBP1 DNM2 NCKAP1L ATXN7 ACADVL SERPINF2 LDB3 TPM2 PLEKHM1 PAX3 ELP1 IRF8 RMRP TGFBR2 STAG2 UQCRFS1 LMX1B SALL4 CFAP300 SIX3 BMPR1A DDB2 IGHM GJA1 HPGD MEFV KCNH2 KCNQ2 PALLD RNASEH2B NDUFAF8 MSX1 NOTCH3 BCL6 ISCU ABCC8 ATP11A FAM111A DBH ODAD1 SDHC CHRNG HBB SALL4 CTLA4 ATP7A RNF213 LOX PIGV CP POLR1A NMNAT1 ALPK3 GPC3 WNT5A CYP26C1 PTEN PPARG BBS7 DDX6 ABCC9 PQBP1 COG5 LMNA ETHE1 LDLR DVL1 RASGRP1 CHD7 TTC12 VCL GABRA3 KRT18 PROC KLLN IARS1 GPI GAS1 KIF23 ACTA2 KCNQ1OT1 WIPI2 THPO FGF8 GLI2 LBR PLCB4 ARID1B BRAF DSP IDUA ANKRD1 BCOR IL12A MMUT SF3B4 PEX7 CFB SCN1B UMPS SERPIND1 PLOD3 KIAA1109 TERT XPC SMCHD1 CD96 MYH7 ACP5 SPEG NT5E DNAJC21 MYCN IGBP1 LMNB1 ACTC1 OTX2 RHBDF2 RTL1 ESS2 FYB1 EXOC6B RPS26 SLC39A4 PIGA MID1 ARL2BP EPHB4 SFTPB ODC1 ASCL1 TTPA PIGL PEX10 ND2 GBE1 TP63 JAK1 DHPS RAI1 XPNPEP2 DNAJB13 COL2A1 AGBL5 CPT2 PROM1 PALB2 IL12B SDHC PDE6G LEPR JAK2 FGG PIGT TSPYL1 STAMBP FASLG KLF13 PIEZO1 EZH2 EPB41 RUNX1 B2M CORIN SPTA1 NR3C2 MYH6 KLHL41 PROP1 ADA2 LIMK1 DSP RPL5 HMGA2 KRAS CCM2 NDUFAF1 ERCC3 IDH3A EP300 NDUFA6 MCCC1 DCLRE1C FARSA CDC42 PLCG2 ACTC1 STAT4 C2 VAC14 PKHD1 DMD ND3 SIN3A COL7A1 CYP3A5 BRAT1 ZMIZ1 NUP107 PTCH1 LMNB1 HNRNPK ND1 IGHM TNNI3K TGIF1 TUBB GJA5 POLG FLNC HAVCR2 SMARCC2 ERCC2 TXNL4A RAB23 CD3E MLH1 BCHE SULT2B1 DISP1 PEX1 LOX DES PIK3R2 BPTF TNNC1 PPP2CA RNF168 TMEM126B FSCN2 ARCN1 PIGV IDUA NKX2-5 IGH CYBB COL5A2 BCOR JAK2 SERPING1 SLC12A3 DOLK NEU1 TGIF1 ADA STAT3 FIBP B4GALT7 ZMIZ1 HLA-B HDAC4 ECE1 CYP17A1 TSC1 ATP6V0A2 A2ML1 DPM3 RP1L1 PKDCC RPS26 MEFV ORAI1 CLIC2 ITCH SEMA4A ASXL1 TRIM8 WNT4 RPS27 SURF1 UFD1 RAF1 SERPINF2 SRP54 SCNN1B GBA DKC1 MYH7 COG7 TCIRG1 ALOXE3 BBS5 SF3B4 LAMB3 VANGL2 MYPN GLI3 LIPT1 KANSL1 PTCH1 EIF2AK3 PPA2 NDUFB10 FBN1 ARL6 ABCA3 STEAP3 GCH1 UNC13D FGFR1 FZD4 HTRA1 SALL1 CPT1A HLA-DQB1 SMC1A PCCB NDUFAF4 FAM13A NEXN KCNN4 LARS2 CTU2 CYP21A2 HSD17B10 TWIST1 SMC3 COG1 ARPC1B FBN1 CALR GATA1 WDR1 ACTC1 PRNP RHAG DOLK RBPJ INF2 HLA-DRB1 HNRNPA1 PHOX2B DPH1 MYLK TMEM94 PRPF4 ADAR SARS2 HDAC8 MLH3 COL4A1 STAG2 LRAT CITED2 EFL1 KIAA1549 TERC BUB3 CRX ITGB3 NSD1 BOLA3 KIAA1549 ATF6 TRIP13 MEG3 PRDM16 KMT2C AIRE MED13L ATP7B AMMECR1 BCR BBS2 GLB1 ABCC8 ACAD8 DSP CYP7B1 MYPN DLL1 VHL EXTL3 SH3PXD2B KCNE5 ARL6 MAN2B1 COMT MYORG ARX EMG1 AIP CSRP3 RHAG RAG2 FCGR2A GJA5 TMEM67 BTNL2 ADAMTSL2 WNT3 DSP SOX18 PIGN PAFAH1B1 HGD ITPR1 FN1 FBN1 PIEZO1 ACTN2 COL1A1 YY1AP1 NPM1 ATP6V0A2 ZBTB16 AHCY EPG5 COL7A1 DDB2 SHH CACNA1C KIT EGFR OSGEP LAMA3 TBX2 SPECC1L IKZF1 SPECC1L SAMD9 LMNA YY1 PIK3C2A LMBRD1 ELN IFT172 PDSS2 DNAAF4 SH2B3 HBG1 NDUFA2 LZTFL1 MYO5B KCNJ11 EVC2 CEP120 SEC63 UNG PTEN MYC GATA4 SLC26A2 SCNN1G NKX2-1 PLOD1 PLEC DLL1 FHL1 MUC1 KYNU ABCA1 TTC8 IGH CLIP2 H19 APOB LAMA4 PLCB3 IL6 GNAQ KCNE1 IGF1R SLC25A4 DYNC2LI1 GNAS GDF1 MYOZ2 IRF5 DST LMX1B ARMC9 NRAS KCNE1 MEN1 SIX3 HJV MYD88 THOC2 PORCN SNRNP200 SOX11 GNB5 SHOC2 CKAP2L SDCCAG8 AP3B1 POLG PDGFB CBL APOC2 POLA1 COL2A1 LPL MLYCD SON TSC1 MIR17HG DVL3 RGR HESX1 LAMP2 RANBP2 SCNN1B ALX1 IFT122 GNPTG NRAS ARL6 FGB STK11 PEX2 MRPS22 GPX4 PCCA TTC37 DACT1 WT1 SMAD4 DAXX KRT14 PACS2 RPS15A RAF1 LRRC6 TRNW DYNC2I2 TNFRSF1B SHH PDE6B WNK1 PKP1 CHST14 TRNV TANC2 KIT FLNA NFIX SLC12A3 ACAD8 PRKCH TBXA2R TRAC TJP2 CCNO FGFR2 IDUA MGP KIT NDUFS3 GBA HRAS FAM161A KCNQ1 NOD2 NOD2 ADK MYCN SLC25A20 POU1F1 TRNH GAS1 AKT3 RAG1 PTPN11 SLC26A2 GATA2 STAR HMCN1 IDH3B SLC7A7 CACNA1S RARB GATA6 DPP6 FGA CBS SUFU TKFC PCCB CASP10 SRP54 SUGCT TNFRSF13C RPS17 B3GAT3 EBP ATP6 PLN TCAP CHRNA3 KCNH1 KRT5 MED12 MRAS LMOD1 TNFSF11 MYLK2 DCDC2 CAT FGFR3 CYP11B1 P2RY11 FLAD1 ADA XRCC4 MECP2 KCTD1 ND3 ACAD9 GBA CLCF1 NUMA1 TNFRSF11A FBXL4 ASXL1 GDF3 F5 MRAS ROR2 NUP107 HCN4 TNFRSF11A TWIST1 CEP290 IRF8 HLA-DRB1 DDX6 TAZ ZIC3 SEMA4A SCN4A NDUFV1 DNAAF1 LPL HOXA11 TRAF7 ERCC4 CACNA2D1 SPTB FGFR1 RBM20 NDUFA13 BCORL1 PIGW SMOC1 KRT5 ATRX ACTG2 FOXH1 COG7 MUC5B GATAD1 PRKCD HSD11B2 BGN STAG2 NPPA NDUFAF3 MYPN PSAP ABCA1 PTEN TNNI3 KCNJ2 RBM10 GANAB TACR3 CD244 PEX14 KANSL1 TNFSF12 MAP3K7 DBH COG2 SDHB IDS DNAAF3 DNAAF3 MC2R BSCL2 TNFRSF4 NAGS MYMK B2M LDLRAP1 CPN1 CAV1 DYRK1A MYOC HLCS ALPK1 KCNJ5 SCN5A SMO NONO FLT4 MAPT LEP CYP7A1 GPC6 CASQ2 TAB2 CPOX ITCH USP45 RYR2 DPM3 ZNF423 CRYAB CEP120 KIF1B SPIB NKX2-5 SELENOI PIGL FGFR1 NDUFS8 NDUFB8 CACNA1C SPEF2 NECTIN1 PBX1 AEBP1 POMT1 RAC2 JAK2 SCN5A COQ4 TBL2 BMP2 BBS2 GINS1 CFAP298 AKR1D1 TBX19 SYNE2 ACTA2 METTL5 DNAH5 WIPF1 POMT1 TLL1 CSNK2A1 MEG3 FGG LMNA KRIT1 OFD1 GATA6 IL12A TPM3 IL6 TRNT LMNA PPP2R1A SURF1 BRCA1 PSMB8 CACNA1C STAG2 CRKL SEC23A CACNA1D CDKN2B GATC SGCD LRP5 ALX3 TAZ COL5A1 MUC5B SEMA3E MRPL12 TCTN1 CDON PROS1 SRSF2 BAP1 FXN PIK3CA FOXRED1 DPP9 ARF1 RAF1 CD79B HEXB SDHC XRCC2 FGFR2 MYPN ZIC2 CALR ITGA7 LTBP2 RPGRIP1 TRIP11 APC SOX2 ABCA1 EXT2 NF1 SPINK5 DSG4 RTEL1 TNNI3 GPC3 TGFB2 SMAD4 DYNC2I1 TPM1 DMPK POMT2 DCDC2 SKI PIK3CA EBP WT1 ANKRD11 NR3C1 HFE SAMD9L TRNW SMC1A KCNE2 ICOS RTTN RB1 HGD F5 FOXF1 CHST14 GLB1 KRAS NCF1 SMAD6 PTCH1 IL2RG B3GALT6 SF3B4 GLI2 RP1L1 OTULIN F8 TET2 SEC23B ZNF148 COX3 OBSL1 WRAP53 ACTN2 PAX3 NDUFV1 ATP7A HGSNAT GLUL CARMIL2 PDGFB ABCC6 STIM1 KDSR DGUOK PTEN TERT FAT4 ALG1 PSEN2 MYL4 COX14 ITGB3 IGFBP7 PHOX2B CHD7 RBM8A ROM1 NLRC4 F10 PTGIS TMEM70 POLD1 EMD TDP2 CACNA1S PRKCSH NUP155 ALPL PKLR TRNL1 CTC1 PEX5 SDHB GATA6 MYPN ALG10B MEN1 NDUFV2 SDHD CCDC39 HEPHL1 HSD17B10 WHCR ACSL4 GP6 MTMR14 COX1 NAA10 FGFR3 EP300 TNNI3 GMPPB NDUFS4 LZTFL1 CTNNB1 INPP5E KCNJ8 HCRT HLA-DRB1 DKC1 TERT SCN10A GGCX KRT8 ERCC4 SFTPB LMBR1 NDUFAF1 RFT1 CCDC65 HDAC8 HBA1 POMT1 SEC61A1 SLC25A11 FLII CLIC2 CPT2 ATP6 DHCR24 COA8 CAV3 LFNG RLIM SUZ12 MARS2 NEU1 XIAP HLA-B BTD SREBF1 FGFR2

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0001626: Abnormality of the cardiovascular system
Genes 4425
MERTK SLC25A26 TRNK MTHFR ALDH18A1 SCN9A B3GLCT GNPTAB MITF GJB4 NDUFS4 MEGF8 SCYL1 TREX1 SLFN14 LMNA DOLK SDHA RANGRF SCNN1G CD247 EFTUD2 KRT16 SLC25A4 NTRK1 ATP6V1A CTNND2 ARVCF SIX3 ND1 WDR11 ANTXR1 CTSB NBEAL2 RREB1 TOPORS NOS1AP RRM2B CAV3 LETM1 GNA11 KIF3B IFT172 NPHP3 COG4 ELMO2 ANTXR1 PEX11B DNAH11 KRT2 APOB RPS6KA3 PRKAG2 GJB6 CDSN ZAP70 HRAS ZIC3 NKX2-5 BUB1B FLRT3 NXN RAF1 NKX2-6 KCTD1 TTC7A SPATA5 DNAH1 BRIP1 FGA SGO1 VPS13B TKFC CRYAB CNBP SEC24C CDK8 TULP1 MYH6 B3GALT6 TWNK PLEC SLC37A4 PIGA TSC1 ATRX FOXF1 FOXC1 WAC GNS TERC MPL THSD1 EVC2 DLST CRB2 FLNB ATP6V0A2 TPM2 AK2 ACTN4 SPAG1 RTL1 ITGA8 EFEMP2 C8ORF37 IL7 KRAS ECE1 XYLT1 VPS45 SLC25A24 POMT2 TPM2 CCR6 KCNE1 PLAGL1 AHI1 SNTA1 PALB2 FOXP1 KDSR RELN CAV1 ARL3 MYF6 IGF2 COL3A1 CBL ATP6V1E1 COL5A1 ACD PPP1R15B ACVRL1 AMMECR1 HNF4A ADA2 CDKN2B ERCC8 SBDS SOX3 FANCL NDUFB11 CPLX1 PRKAR1A LYST PRPH2 SLC18A2 RINT1 COX10 SLC2A1 VPS33A LDB3 XK TTN NKX2-5 GJA1 NGLY1 GLI2 ODAD4 MYH11 MAF FLI1 SMG9 SDHA AGPAT2 CAV1 MKS1 TAF2 LRRC6 COL11A2 HOXA13 CASK CCBE1 SMPD1 BTD KCNMB1 TDGF1 PIK3CA WDPCP LACC1 KCNJ2 ND4 RPS19 CHRNA7 IGF2 KAT6A AIRE DISP1 MYD88 DHDDS GNAI3 DOCK6 KRAS IRF8 ERMARD BAP1 APP RPE65 SLURP1 CALR FN1 SLC19A3 ALX4 TSPYL1 PEX13 SLC39A4 NDUFB11 TTN FOXC1 RBCK1 HNRNPA2B1 TRPM4 ZIC2 WDFY3 KYNU PSMB9 CD2AP APOE SMAD4 ITGB3 TRNK KCNQ1 SNX10 KCNJ2 HMBS FKBP14 FGF8 BRAF SC5D SHH ALOXE3 FAS SCARB2 HACD1 CREBBP CITED2 MMP2 HADH NEXN NODAL ABCC6 PORCN CEP57 PIK3R2 RAD21 SCYL1 VCP KCNE2 USH2A TCTN3 PTPN22 ESR1 TRNS2 CDON TIMMDC1 C1R STRA6 IL10 DLD SCNN1A DNM2 SOS1 CDKN1C TGM1 TNNC1 LPIN2 CCN2 MAP3K7 HLA-DRB1 FRG1 TSC2 PPP2R5D GLI2 SLC2A1 EYS FDFT1 IFNG ANK1 SYNE2 ARL6 IRF6 TAB2 PCSK9 TP63 CARS1 HABP2 MYSM1 ERGIC1 ALOX12B DYNC2H1 DSG1 NSUN2 FLT4 FERMT1 DNAL1 CRYAB PPARG GNB5 TRNE TSFM MEIS2 DYNC2LI1 TRNL1 NT5E EWSR1 POU6F2 CSGALNACT1 ELN PRCD FBN2 KAT6B PLCG2 THBD PEX5 SLC2A10 SPOP GBA CYP17A1 SHANK3 SGCG TRNK PNP ACTA1 AGTR1 FERMT1 SIM1 GNA11 DGCR2 NCF4 ODAD2 FMR1 CYTB HCCS GBA SNIP1 DNAI1 LMNA PSMD12 NBEAL2 MKKS LMNA WAS DMD NDUFA10 ITGA3 HESX1 PIGL SDHAF1 POMK MKS1 CYP11B2 ATAD3A IL2RB CACNA1S GLI2 RNU4ATAC NEU1 TASP1 PMS1 RNASEH2A FAH BRCA2 ODAD3 FKTN FHL1 IL17RA C2CD3 CALM2 MCTP2 PDE11A IGLL1 ODAD3 ATN1 TPM3 MYOT SMOC1 PUF60 SOX10 RYR1 NDUFAF6 TRIP4 IQSEC2 GATB ADAM17 SDHB GLMN LRRC32 TMEM216 NLRP3 CISD2 BAP1 MED12 CYBB COL1A1 STAC3 BSCL2 PTPRC VWF CHST3 FOXH1 NDUFA2 TNNI3 YWHAE SNX10 COX3 COG8 LRRK2 FBP1 TMTC3 GNPTAB CTSK TREX1 XPR1 HADHB ZFPM2 SCNN1A PCARE STRA6 NDUFAF2 IL17RD RBM20 FANCB GLI2 CLCNKB CCDC141 RPGRIP1L PHKG2 F7 RPL10 COL4A1 WDR26 HMBS EGFR ABCC8 PLAGL1 BCR NDUFAF2 CCDC22 SAMD9 DMPK ERCC5 SCN5A USP18 HYMAI C1QBP PRRX1 SLC29A3 ARMC5 PLAG1 COLGALT1 KAT6B MEFV DNAAF2 ITGA2B KDM3B GJB2 NFKB1 IL1RN EED IRAK1 FHL1 TGFBR1 REN ABCB4 COL4A2 MDH2 CALM1 UBE2A SP110 PIK3CD SRD5A3 ENG MAX ATP6 NSDHL HSPA9 PROK2 SETD2 CTLA4 SMARCD1 SOX2 ND5 PQBP1 TELO2 F10 DZIP1L JAG1 GATA6 JAM2 MYH7 KRT14 ALB PEX5 TTC8 ADA2 BPGM RIPK4 FRG1 CIB1 KCNH2 CHCHD2 TSR2 POLR1A WNT5A TET2 RGR SOX9 TGFB3 TMEM67 BMP2 CEP41 GYPC ZNF462 GPC4 FBN1 DDRGK1 COX6B1 RBM10 CFAP410 FGFR2 GDF6 TF MAP3K1 ATP2C1 BMPR1A BBS12 DPM1 MDM2 PARN RHOH NFKB2 RFWD3 VHL H19 TBX1 LIAS MOG TLL1 PPARG DCLRE1C NAXD ABL1 CFHR1 SELENOI GNAS NRL KCNE3 NHP2 CYP11B2 TGFBR3 KRAS NTNG1 OSTM1 SLC17A5 SDHB ABCG8 COL5A2 NODAL F13B SDHC TNFRSF11B IVD F9 IRX5 GDF2 PSMB4 PCNA PIGU SAMHD1 NXN DSP ANTXR1 UBR1 FGFR2 PEX6 NKX2-5 COL3A1 TRNL1 ARHGAP31 MS4A1 NODAL USB1 BBIP1 F13B CASP8 CAVIN1 CYP11B2 ASXL1 IFNG FGFR1 ARX PLAU PROC RLIM DTNBP1 ZNF408 SFTPA1 TRNS2 ITPA JAK3 BMP2 BAP1 NBAS FZD2 ATP6V1E1 BTK ATM CACNA1S HADHA MCIDAS NOS3 NODAL PTEN ZMYND10 NFIA ACTA1 PSAT1 SYNE1 BCOR ABCC9 CYLD CD81 COL3A1 GJA8 FGF8 RPGR SCN3B COX3 RPGRIP1 CPLANE1 CYBC1 FANCD2 FGFR2 RAG1 CRLF1 SMARCA2 NPHP1 MYT1L ACE CLEC7A GLI3 CYP27A1 FRAS1 NFU1 PMM2 PAFAH1B1 ZMPSTE24 CEP41 DLL1 FERMT3 CCNQ PTEN EYA4 NPHP1 KCNN4 PRDM5 HFE MPL SIK3 SLC40A1 TERC RPL27 SEC23B TRPV3 PPOX TCF3 SUMF1 SDHAF1 COL1A1 STAT5B SUFU CREBBP SOX9 STK36 BBS4 SLC7A7 GJA1 ADD1 DOCK6 CD46 DIS3L2 MFAP5 KNSTRN ARX TNNT2 SF3B1 KMT2E INPP5E BANF1 GYG1 ARHGAP31 ZFPM2 RMND1 ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 XYLT1 ERF PEX19 ENPP1 MED25 NCAPG2 FOXH1 HJV SEMA3E AIP IKBKG IQCB1 MRPL3 SP110 NAGA MED13 LIG4 NDP HPSE2 TRPM4 FZD4 FLNB FCGR2B LHX4 INPP5E KATNIP TRIP11 TTC8 PSAP TREX1 ND2 ND5 IDH2 BRCA1 RPS6KA3 FHL1 USP8 SLC25A11 MASP1 LMNA LMNA WDR37 TRPM4 PEX3 TRNF OTC FADD OTC TMEM126A MTAP PPARG TRNQ KIAA0586 ZMPSTE24 RAI1 ELN KPTN LBR KDM6B SON AGXT TRNS1 PDCD10 CYP7B1 TRDN DMXL2 SPATA7 NPHP3 TRAPPC11 ELN PTCH2 MAP1B TGFB2 ARHGEF18 JAK2 SUMF1 GUSB ADCY5 IFNGR1 DHCR7 GUSB KITLG HADHB BVES C12ORF57 SDHB GBA MPIG6B FOXP3 RAC2 STIM1 KRT83 RPL35A AKT1 MYH6 ZFPM2 GJB6 CHST3 KANSL1 PURA SATB2 PITX2 COL4A1 FN1 GLRX5 ADAMTS10 CDK4 AFF4 ZFP57 ERCC1 SCARF2 PCNT PRPF8 NPHP4 LRRC8A RPL26 RMRP ACTG1 TTN OTUD6B KDM6A ECHS1 KCNQ1 ATP5F1E CTCF TGDS CNGB3 TMEM107 GAS8 POLG DNAAF2 SCNN1A ACTA1 MTM1 FLNA POMP HABP2 MTTP TRNL1 FGFR1 TGFBR2 FKRP OTX2 PTPN22 CFI LRP2 PHF21A ZIC2 EOGT RNF6 PLIN1 INSR WRN KRT5 PIGN NDUFA10 FKBP14 WWOX PPA2 LDLR GATA4 GATA6 TBX1 ENG POLH NSMF ARID1A KCNK3 NSD1 F5 KCNN3 REEP6 NKX2-5 CREBBP KIT ZFPM2 CDH23 PDE6D ATP6V1A TMEM231 MTFMT PROS1 XYLT2 EPCAM KCNQ1 P2RY12 IL10 PDGFRB SLC4A1 LRP6 NDUFS8 GCK SDHD DCAF8 STRADA PNPLA2 NDUFB11 DDRGK1 FUCA1 RNASEH1 RNASEH2C ND4 NF1 AKAP9 NOTCH3 FLNC DNAAF5 PEX5 PDHA1 SMARCE1 ERCC4 MYH9 CCDC22 COL1A2 STAT3 CCND1 TMPO ND6 IMPG2 CALM1 CCDC8 TGIF1 NEUROD2 DNAH5 ABCA4 TRAF3IP2 ARFGEF2 TBX1 KISS1R SSR4 ALG8 DDX3X TRNS1 KDSR HAAO RIN2 TUB MKKS RSPO2 DNMT3A ETV6 GNB3 HK1 AFF4 GBA RAB3GAP2 PPCS FGB IL23R DVL1 F8 FBXW11 APOA2 CYBA RAI1 MYH11 CITED2 PEX12 TFAP2B HADH SCN9A FGF8 CASR POLE LOXL1 ICOS FADD AMMECR1 SCN5A LMNA TNNI3 CDON PDE6G SDHD MANBA PIGT TDGF1 DYSF CCDC40 ALMS1 FGA ANO5 PARS2 RPGRIP1L TERT GJB3 CDIN1 KCNE1 FOXH1 SOS1 NRAS CACNA1D WAS CASR DHODH F2 PNPLA2 EHMT1 NF2 TCIRG1 DYRK1A NDUFS1 FAS MYH7 TOP3A SAMHD1 WDR35 NSMCE3 PTEN TGIF1 G6PC1 CCDC28B KRAS GTF2I TNFRSF1A FBN2 TWNK HGSNAT GNAQ PRDM6 APOA1 DSC2 SRD5A3 IFIH1 FTO KCNJ11 GNAS AMER1 SETD5 LIPC COX2 MINPP1 NFIX RNU4ATAC OFD1 RASA1 AIP COL6A3 WDR35 FAS ACVR2B RNF135 CDH2 SFTPA2 MKS1 UPF3B ANTXR2 PRF1 KRT1 AARS2 TSHR TRNT1 SCN5A GATA1 NRAS GREB1L ERAP1 RAB27A SCN10A MC4R PACS1 PRKACA GLI3 LYST GBA GATA4 TKT TBX4 MYMK COL4A4 SCN2B CEP290 KLRC4 SCAPER MMP1 KRT9 F13A1 VIPAS39 PRPF31 PIGN HLA-DRB1 AIPL1 MPL ADAMTS2 TMEM237 CD55 MVK NKX2-1 DLK1 TPI1 APOE GNAO1 WT1 ELANE GTF2E2 PKP2 ABCC9 GPR35 CIITA TRAPPC4 MED12 CDKN1A CLCC1 CRPPA GJB3 MEIS2 RAF1 MIPEP PEX1 COX3 COX7B NEBL SH2B3 ERCC3 ERCC2 KCNAB2 TAB2 CTNS SETX ANGPTL6 CD19 TRIO STK4 POLH ERCC5 GALNS POMT2 NFKBIL1 ADAM17 TET2 NAA10 SF3B1 SLC26A3 GFI1B KMT2D ABCA12 LRP5 UBR1 PEX3 FEZF1 COL7A1 HSPG2 TRPM4 TRNK NDUFAF4 C12ORF57 MYBPC3 GTF2IRD1 CAVIN1 KRAS PIGY VWF TGFBR2 SPINK5 RASA2 APC PHGDH SLC25A24 NGLY1 LARP7 STAG1 RYR2 CCND2 FANCM UCP2 RPL10 CDKN2A DSG2 ANO10 NELFA NLRP3 KCNJ11 PIK3C2A GLI1 CTCF KCNQ1 LRP5 TCF4 CFHR3 POLG TBX5 SHPK HLA-DPA1 TMEM43 SETBP1 LMNA RIT1 SVBP CEP164 AKAP9 ATP6 FKRP CYP27A1 CACNB2 WAS SDHA NF1 LAMB2 BAG3 RARA ACTL6B TREX1 ABCC6 COL11A1 HSPG2 KCND3 CNGA3 IL36RN SLC19A2 CYP1B1 COL3A1 CD96 CYBA ERCC8 TET2 GLIS3 DLD TERT PEX2 FOXH1 SURF1 ATOH7 GFI1B HRAS CASP10 TSC1 TNPO3 NIPBL PITX2 WDR19 GAS1 MYCN TXNRD2 IL10RA ATP7A MYH9 ACTA2 TRNW GDNF CTLA4 PDE4D SPTB ADAMTS3 GLB1 SGCD ERCC3 F7 HLA-B COL5A1 CBS SNCA FGFR2 LIG4 RNU4ATAC CLN3 GNE AKR1D1 ADA2 KCNJ1 FGFR1 CFI ERCC2 DISP1 FKTN ATP6AP2 NLRP3 FGFR2 COQ2 SPECC1L ARL6IP6 FAH ND5 NR0B1 LIG4 MAP3K20 POMT1 FOXE3 PDGFB GYS1 SDHAF2 SLC26A2 FAS PRKAR1A SERPINC1 RLBP1 TCIRG1 CALR PIK3R1 LIFR KCNQ1 SDHD ZNF687 SLC35A2 FGF8 CCDC40 CTLA4 SCN5A HBA2 ARSA DCAF17 CFTR SCNN1G ESCO2 GJB4 ITGA2B KIF1B BEST1 RP2 GATA6 BBS9 ARNT2 KCNJ18 HTRA2 SPRY2 STAT1 GTPBP3 FGF8 SCNN1A SNRPN MYOC GPR101 ATP5MK HNF1A MAX LRIG2 LONP1 PLEC CXCR4 ERCC8 COQ9 PTDSS1 SLMAP STIM1 CCND1 KCNQ1OT1 AHCY ATPAF2 FANCC POLR3A SKIV2L PADI4 CYTB MAF TERT SFTPC FOXJ1 NPC1 AICDA FANCI CALM3 NDUFS2 EDA LDLRAP1 TFAP2B CALM3 PEX6 CFAP298 CSTA SELENON TRIM28 ZIC2 KLHL7 NPC2 TBX22 ALMS1 GPD1L FGF8 ELN SBDS CERKL CYP11A1 KDM6A LAMP2 B9D1 MAFB DTNA NDUFS2 PEX14 LEMD3 GJA1 FGF20 SGCB MMEL1 DNASE1L3 TGFB3 CCDC141 FANCA LIPN FLT4 MYH7 RDH5 SCNN1B FBXW11 MAN2B1 SCN5A LTBP3 PTCH1 MGME1 EPG5 NKX2-5 GAS2L2 PPP1CB F13A1 PDE6H HIC1 CBL CWC27 PDE3A FLNA CHRM3 POLG2 JPH2 IRF5 IL17RC GNAQ SMARCA4 APP PIGM HPS5 TMC8 COL4A5 LYZ NFIX RTEL1 PRKG1 PLN ATAD3A MPI BRAF IFT172 FMR1 ALG14 PAH WRN TGFB1 RBM8A NDUFB9 SFTPA2 CDH23 FGFR3 RET NR2F2 JMJD1C TNNC1 SLC30A10 GLI2 BUB1 GMPPB NRXN1 COQ7 OCLN VCL TMEM237 TFAP2B TBX1 WDR19 RRM2B COX4I2 KAT6B FLNA DNAI1 HCCS NOTCH1 IFT140 FOXA2 MPLKIP PROS1 LZTR1 SOS2 NDUFS2 CACNA1H TPI1 FECH CYP11B1 GNA14 MADD GCDH PEPD MYT1L MYO18B GTPBP3 SDHA IDH1 CDKN2A SCN4B SOX10 FBLN5 YY1AP1 CDKL5 RPS10 TANGO2 NPPA GAA AKAP9 NDUFS2 PIGO MAP3K7 LMNA MEOX1 KRAS TMEM216 RBBP8 KLF1 SCN1B BPTF SMARCB1 SOX10 BRCA2 SPTB ANK2 RNF113A BRAF MBTPS2 RAF1 COL6A1 FASLG TNNT2 CCDC39 DNAJC19 PYCR1 SMN1 EYS TNXB CFH DEAF1 LMNA PSMD12 TK2 INTU ATP6AP1 PEX6 POGZ STAT3 PLG CHRNA1 ACTN2 NEK9 ESCO2 LONP1 TGFBR1 ACAD9 CDH2 POLG TMEM127 LPIN2 KYNU PRDM16 SETBP1 SNRNP200 CFH UVSSA UBE3A MYH7 PRRX1 CPLANE1 TBX20 SFTPC SLX4 CARD9 ARL2BP RECQL4 LEMD3 TNNI3 RPL10 FGFR2 FHL2 GABRD IRF2BP2 EHMT1 NEK10 ABCG5 MYH7 RPL5 CRYAB MKS1 DOCK3 NODAL ABCC9 TFAP2A RPS24 VPS33B RPL35A FGFR2 SGCA RET COQ2 ARL13B IDH3B MGME1 ASAH1 NOTCH2 UBE2T CENPE CHRNG ATRX SNTA1 PRPF3 ERCC6 HBB MED13L KCNQ1 MRE11 JAG1 RECQL4 RPL27 DNAJC19 TDGF1 TALDO1 RNF213 RAI1 HFE NDUFS2 NR2E3 PCARE MAK PHKA2 LAT STXBP1 ZEB2 KDM5B PIGO MAP2K1 PIBF1 PAX6 ERCC4 SOX18 ERBB3 SIX3 ROR2 ND4 BMPR2 CENPF PEX16 PDX1 DUX4 PEX19 FLNA DIS3L2 DLL1 CDON SHH TPM3 CPT2 H19-ICR TBCK MTRR BMPR1A MYL2 HBA2 JAK2 FOXC1 TBL1XR1 GDAP1 RAD51C CACNA1C RRAS2 PRPF6 LIG4 AGK DNAAF6 PIGS RNF125 BIN1 NR3C2 FANCA PRKAR1A GDNF MYPN NOTCH3 IGF2 RUNX1 PRKCD BLNK KRT1 PRPF3 FCGR2C KAT6A FBLN5 ABCC9 GCLC WDPCP IRF5 WT1 LIPA RAB27A KIT TMEM43 ADA AUTS2 CYTB SALL1 SERPING1 CYP24A1 TGIF1 ASCC1 DNAH1 CSRP3 GNE CST3 IGH FAT4 JAK2 PSEN1 G6PD ACADS MYH11 TMEM43 INSR ERCC6 PQBP1 ARID1B ARL3 PDE6A SH2B3 PPOX TP63 SHH PLOD1 AKT1 TTR COPA PEPD SRY SCNN1B FBN1 SNRPB RBP3 GAA CALM2 GATA6 DYNC2I1 CASR ZNF423 RAD51C GALE SDHB HPS3 REST TGFBR2 SCNN1B TAZ PKD1 TPM1 PRKACG HIRA ACTG1 DRC1 SVBP GPC6 GDF1 HOXA1 BAP1 COX1 CSPP1 ELN MGMT ARSB PEX6 RPL11 PET100 RIPK1 CASQ2 ACTB MSX2 ND2 FOXP3 USP9X ND4 SOX4 SLC39A13 PKHD1 CHKB COLQ TTR SPEG RPL11 GLRX5 PAM16 NOTCH2NLC TET2 SCN5A AKT3 PTPN11 MEOX1 RP9 F2 ENPP1 RHO POLR1D TDGF1 TNFRSF13C GLA SELENON HSD17B10 RPL15 TULP1 NF1 ADGRE2 FGB MED13L GATA5 AGL DDC TRMU BACH2 DLX5 ZNF513 IL12RB1 SH2D1A KRAS SLC25A4 SCN5A NDUFA11 GSN CAP2 ALDH18A1 SMAD6 VPS13A EXT2 ITGA2B SLC4A1 FRAS1 NDUFA12 MFAP5 CYSLTR2 CEP55 AGXT FGF17 CLDN1 PDE8B MAGT1 FGFR1 IFNGR1 DES SMAD4 ZNF469 ND1 DOCK8 KMT2D SOS2 SLC19A2 ND5 LAMA4 CTNNA3 FOXRED1 LIPA MICOS13 CSPP1 ACAT1 RORC STING1 DCHS1 GATA3 MEGF8 HLA-DRB1 ZEB2 ARID2 CHN1 PIK3R2 RPL18 STN1 HTRA1 AP1B1 PCCA EXT1 CCND1 CYLD PDGFRA RAC1 KIF15 TBX20 FIG4 SLC20A2 BIN1 LIPA ODAD2 FLNA TRAF3IP1 SMO SLC4A1 PDHA1 DNAH9 TMEM231 GLA SCNN1G NOS3 MBTPS2 EVC NSD2 HS6ST1 DPF2 ITGA2 MAN2B1 PIK3CA LRP5 PKD1 KIF1B APP TNNT2 TNFSF15 PTCH1 LRP5 RBP4 MMP2 LMNA NLRP3 CHD4 LRRC56 FGG ABCC9 CYP11A1 RNASEH2A CIZ1 TNFSF4 ODC1 POLR3A AGPAT2 TWIST1 MMP1 NDUFA4 ND1 IDUA COG4 TP63 PAFAH1B1 PTCH1 PEX7 LCAT COX8A GP9 ABCD3 PRPH2 TP63 DISP1 TCTN2 TNXB SCN1B PPP1CB VANGL1 NR5A1 NKX2-5 TSC2 ACTA2 DGUOK GFI1 MAPK1 IFNG COL1A2 NDUFS3 PHYH MESP2 RPS28 FASTKD2 FOXE3 NLRP3 MRPS16 RAI1 NABP1 SCN9A PCGF2 FLCN DNAJC13 SFTPB ACTC1 PLVAP HBB RPS20 RPSA RAD21 INVS LYST NDUFA11 RARB CD19 BMPR2 DZIP1 APOA1 GATA1 PEX7 NEK2 ATM LMX1B GBA APOE TGFBR2 MYH11 CANT1 RECQL4 HYOU1 IGSF3 TOR1A ATP8B1 CFTR EVC FANCE PARN PRKAR1A TGFB1 MYLK WWOX MTOR RFC2 WDPCP GATA4 RRM2B CCDC103 SETD1A NEB MPLKIP POLA1 FLT1 CD19 CALM1 SIX3 SMPD1 B9D2 SERPINC1 SELENON SPARC HPS4 PTH1R SRCAP ATM MNS1 KRIT1 MYH6 SH3PXD2B GNAT2 CLCN7 TRIP13 HAND2 COL18A1 MST1 ANKS6 RPS6KA3 MEF2A ALDOA FGB FKRP NOP10 AVPR2 COG6 TRNQ BCL11B PRDM16 IVNS1ABP STOX1 ASAH1 ACTL6A NDUFS7 SMAD3 TALDO1 NUBPL CITED2 ERCC2 TAF1A COL4A1 COX15 TEK STEAP3 HADHA ALX4 ACTA1 DSP NDUFB3 EIF4G1 GATAD1 ACTA1 HBB RERE FLNA MAD2L2 CLRN1 LTBP4 PNPLA6 TMEM237 AIP DDX58 POR PGM3 DCC ABCB11 KCNJ8 EOGT VHL PIK3CA MTFMT TEK PLD1 SLC25A4 SDHC DCLRE1C SEC31A TLR4 RSPH3 APOA5 COX7B CYBC1 DCHS1 KCNH1 FANCB BBS2 HBB SRCAP GAS1 TNFRSF13B LMNA CRB1 ZMPSTE24 ANOS1 SMARCE1 KCNQ1 BCOR WARS2 KLHL3 STAT4 SMAD3 GTF2H5 TRNV RUNX1 LRP2 OPA1 PRKAG2 DNAAF4 UBAC2 MAP2K1 RIN2 THOC6 DLEC1 BIRC3 COL4A3 FGA TTC8 SCN1B GATA4 TMEM138 CD27 BMPR1A ALKBH8 CFHR3 MTHFR NSMCE2 VCL MITF QRSL1 DHCR24 CAV1 BNC2 SNAP29 ITK BICC1 RECQL4 THOC6 NAGLU TRMT1 AKT1 JAG1 RERE GDF6 DMD F2 FIP1L1 GJA5 C2CD3 ND5 ATP2C1 APC NFIX NDNF B9D1 ICOS GFM2 SARDH ND6 HLA-B PRKAR1A KCNJ18 MAGEL2 GMPPB NF1 MAP3K7 DLL1 RPS29 NODAL LRBA RDH12 PLP1 RSPH4A TERT FBN1 F5 NAGA RHO ATP6V1B2 RET HSD11B2 WASHC5 TCTN2 DMD GANAB TMEM67 C8ORF37 SLC39A13 CD46 ADAMTSL4 VPS33A DPF2 PIGQ INS SDHA MVK SMARCB1 RPS7 WT1 TRAIP NDUFB11 DNAAF1 TOP3A PRCD CUL7 TCOF1 ALG9 TRNC CALCRL F5 KAT6B POMGNT1 TTN OFD1 EPB41 TERT BRAF CLCN2 APP SLC2A10 RPS15A APP KRT14 GJC2 PTF1A MALT1 HPGD NID1 SOX3 KCNH2 ABCG5 FSHR MAFB DSE GATA6 CFC1 EFTUD2 HBB MYL3 RPL15 PPCS STK11 ALB CDC45 SNAI2 PCNT FOXH1 ESPN TPK1 IDH3A ANKRD11 COL1A2 TARS1 PKLR CEP290 WNK4 CCR6 SH2B3 ALAS2 DNAH9 HSD3B7 PLIN1 BRAF ADNP DSG2 UROS RLBP1 EXT2 TBX1 SMCHD1 PIK3CA TCAP RS1 ATP5F1A GATA6 FANCG SCN5A GP1BA NDUFV2 GMPPA NOTCH1 MAB21L1 ADAMTSL1 AKT2 MCCC2 ND6 DNMT3A SIN3A THPO NOD2 MYH6 WASHC5 CPOX FOXC2 HAMP GJA1 ANKRD26 ACTA2 CYB561 SCN1B PIGT VPS13B PRKCD HYLS1 SUFU PTCH1 DNAJB11 HOXD13 IGF2 TRRAP CFAP300 COL1A2 GDF1 MTO1 IFT27 INTS1 PHKG2 PEX19 MAP2K2 WT1 DLK1 PPP1R17 SMC3 CR2 STX11 F12 MED25 MADD COL6A2 RAB23 SHH ACADVL FAN1 TET2 TKT MYRF HRAS DLL4 F8 MVK CRELD1 GALNT3 SCN5A TPM1 KIAA0753 SCO2 SOX2 ATP8 SLC26A2 PUF60 RYR1 ELP1 AGA BEST1 NLRP3 FANCF VWF FBN1 MMP21 TCIRG1 PNKP F2 CPT1A FLI1 ZIC2 SLC29A3 KIF20A DLL4 IMPDH1 MBTPS2 POLG KRAS SIX3 PEX12 PRKCSH TCTN3 SOX10 SMARCB1 TRNN SCO1 BTK MSH6 KRAS BSCL2 RSPH1 SMAD9 CCBE1 GK DNAH11 AGTR1 ATR CSF2RA NADSYN1 UMPS CDC42 GJA1 LAMA2 SMAD4 SACS TCOF1 NTRK1 DES POMT2 SLC22A5 MCFD2 MYBPC3 XPNPEP3 NOTCH2 SKI SEC23A TTN LORICRIN MRPS14 SYT1 ODAD4 ECHS1 IDUA CACNB2 DLL1 ND1 RNF113A TBX6 RERE FLNA CASK DGCR6 TTC7A SFTPC RAG1 UROS INTU CKAP2L EDNRB NLRP1 IFT81 ABCD4 EPHX2 COG4 EED SIK1 ETHE1 RPS19 IL12A-AS1 ENG CDKN1B HLA-DRB1 HYLS1 NPM1 NDUFS4 MC1R SCN11A TACO1 RB1 CTLA4 PRG4 CEP19 KLF1 C1S CRELD1 PHYH DSE PEX1 ERBB3 RPGR TCF20 LIMS2 GUCY1A1 GALC TUBB RET JUP NLRP3 ALDH3A2 DHX38 IFT80 FGFR3 FXN FGA MKS1 SEMA3A HBA2 NPHP3 WFS1 VHL PMM2 COL4A3 BRAF ABCB6 IDUA MNX1 PRPH2 RPGRIP1L EYA4 FBN1 HBG2 SLC29A3 CNTNAP2 RAG2 CAPN5 CTSA PGM3 CHRNA7 FANCE MPL COL7A1 NDUFS6 HIBCH FKTN ZEB2 XPA NEK1 GJA1 TRDN FLNC ENG AKAP10 KIAA0586 CCNQ PLN NDP AGA LAMC2 RAG2 IL17F VAMP7 CEP104 FANCC SNCA PYGL CCN2 TPM3 TWNK GGCX COQ2 FOXE3 NCF1 CD3D ABCA4 TAF2 RIT1 MGAT2 SAA1 KIZ IL7R TBC1D24 TTC37 LTBP4 SPTA1 MLX COL1A2 IDH1 SMAD3 TGM5 FOXRED1 PEX16 NOS3 GHR DDX11 HYMAI GDF2 PRKAG2 HLA-DRB1 MRPL44 NDUFA1 DNMT3A NEU1 ATIC EDN3 FLNC CPS1 PRKAR1A APRT GPIHBP1 DNMT3B IDH2 SCN3B PTPN11 EDN1 MECP2 AGK NDUFV2 USF3 ACVRL1 TFR2 FLNA MTTP NRAS OTX2 CC2D2A DNAAF6 FGF23 CLCN7 ANK2 NOTCH1 FBN1 NUP188 NDUFAF3 STAT3 PEX2 PEX10 CARD11 TBX5 BAG3 ERCC6 STX16 SMAD4 SLC25A13 PGM1 LRP1 JAK2 HMGA2 AHI1 RPL31 ELOVL4 AQP2 PIK3CA TP53 CNGA1 BRCA2 PALB2 GAS1 PSAP PTCH1 CFI PTEN STAT3 TMEM67 SCN10A KBTBD13 TREX1 AHI1 ACTC1 JAK2 ISG15 MYH7 ACTG2 BEST1 TMEM126B MAP2K2 ACADM DLL3 RYR1 FUT8 PEX12 ASXL2 KIF11 GP1BB MSL3 HADHA TERF2IP SH3BP2 HNRNPK NFKB2 FREM2 IFT172 HIBCH PIGY ANK1 TGIF1 CAV3 IDS AVPR2 NEK9 SELENON PSTPIP1 CCM2 LEMD3 ATAD3A GATA4 NR3C1 NEUROG3 SCN2B TBX1 POU2AF1 TDGF1 PRKACA ADNP CA4 CD28 CDC73 SIX3 PML BLOC1S3 KCNJ5 CHD7 POLR1C POR TNFRSF11A FH ATRX HES7 FOXC2 NKX2-6 FOS GLB1 CC2D2A DSP MYH3 KRAS HSD3B7 ALDH18A1 ALOX5AP PEX11B SDHD DVL3 SLC12A1 SCNN1A PSEN1 WFS1 GPC3 DCTN1 ALG9 DNAAF5 JUP ZMYND10 CACNA1D IL2RG IL7R PTH1R SMPD1 HLA-A ROR2 GP1BA SMAD4 KDM6A NONO INVS TLL1 RIPPLY2 CLCN7 MYLK NODAL ND6 SERPINA6 GNE BAG3 MEN1 LRRC56 GATA1 TSC2 VPS35 DHCR7 WARS2 NDE1 SLC20A2 WNT10A SLC7A14 GSN RP1 KCNJ5 BMPR1A LBR ARID2 BBS1 SDHD ZNF513 RET CNGB1 KCNJ5 SETD5 NKX2-5 CAV1 ABCG8 DCAF17 DSG2 TF GPD1L AGT GATA1 CTBP1 BTNL2 RYR1 SNX14 CHST3 RAD21 SOX4 SAG ERCC6 TP53 IGF2 BBS10 FUZ SUFU CRTAP PSAP PEX13 GAS1 B3GLCT ABCC6 PLEKHM1 ADAMTS10 ELN RET GATA5 ALDH18A1 CALM2 GATA5 EPB42 GP1BB TCIRG1 DIS3L2 CAV3 TPM2 EMD SCO2 TXNRD2 IKBKG FUCA1 SPAG1 ARID1B GNAS AGGF1 F8 ABCA3 ND4L NLRP12 TGFBR1 NDUFAF5 NOTCH1 PMS2 SEMA5A CAV1 NDUFS8 CD28 CDON GPX4 CA2 CC2D2A PDGFRB GREM1 KIF7 STXBP2 TGM5 ADCY5 EPHB4 ESCO2 FHL1 NEDD4L BCS1L IFT88 CITED2 NDUFB11 BCL2 INPPL1 KRAS CYTB KIT MYBPC3 RPGR CALM1 GRIP1 ATP5F1D FANCD2 PTPN22 FAT4 IFIH1 IL7R LMNA JUP GPC4 FECH H19-ICR SMARCAL1 NAGA GBA CEP290 PDCD10 DISP1 HYDIN SPRY4 MAP2K2 IL2RA FGD1 CDK13 CTC1 PDSS1 PNP PRTN3 ARID1A EPB42 XYLT2 MYH6 FRA16E GP1BB RSPRY1 TRNS1 SDHD BLM CASQ2 CALM3 RRAS SALL4 FANCI LMNA DDR2 ZAP70 ALDOB MNX1 LMNA AIP ND4L C3 IFIH1 TMEM260 NRXN1 USP8 FGFRL1 DPH1 APOE C8ORF37 AP3D1 SALL4 BRCC3 ABCA1 CDK10 KDR TECRL AAAS TBXAS1 C4A MYH7 SH2B1 ERCC6 SBDS DNAI2 NKAP TBC1D24 PEX1 LIPC CHRM3 MTHFR MYL2 TRNE COA6 SERPING1 GATA6 BCL10 PRF1 RAG2 SCN4B GBA GATA4 SMARCA4 GM2A CD40LG KCNQ1 MSH2 TRMT10C MMACHC MIF HES7 GP1BB HLA-DQB1 TRIM32 NKX2-5 GMPPB SLC35A1 AMER1 EIF2AK4 SPP1 XYLT2 KIF7 LBR NCF2 MKKS PTPN22 TMC6 CEP57 FGFR2 DNAI2 SDHA SDHB TRNF TPP2 SDCCAG8 SOX5 PCNA ZNF469 RAG1 CDKN1C CDC73 IFT43 CEP120 HAVCR2 HMGCL KCNJ2 HBB MIB1 SLC4A1 ACP5 XIAP CFAP53 IL2RG ATP7A RNASEH1 FANCB CYP11B1 KAT8 BTK SDHB TTN TMEM231 OFD1 TET3 KLHL7 CDON PTPN11 TXNL4A PHGDH LRP5 FLNA PIEZO1 PIK3CA NNT ABHD5 DVL3 KCNE3 AEBP1 RYR1 CDHR1 HCN4 STRADA PSMD12 CUL3 SLC25A3 ANAPC1 LONP1 ERCC4 FBLN5 ATP6 FBN1 CLRN1 PEX16 FLT4 NIPBL SMAD4 LIPT1 SLCO2A1 NOTCH3 CD109 RPE65 CHD7 SLC37A4 COQ2 TNNT2 SRP54 CD79B SOX18 SGCD TSHR AQP5 TNNT2 CDKN2C MMP14 MED12 TGDS CCDC47 PKD1L1 ND2 ADAT3 CPOX RPS17 APC2 MYH8 TRAF7 KIF7 MYH7 SCNN1A GPD1 DHX37 VEGFC KRT5 TNFRSF1A KIAA0319L CLCN7 YARS2 TBX1 PDE11A SMC1A PIEZO2 TMEM237 NDUFS7 PDGFB TBX1 KCNA5 AKT1 TNFSF12 EFEMP2 PGAP3 ABL1 PIK3CA EHMT1 PDGFRA CTNS SDHD NCF2 NDUFAF5 TNFRSF1B WNT10A FOXP1 PSTPIP1 BCOR TMCO1 GYG1 KDM1A SDHB NDUFS1 NSD2 TECRL F13A1 B3GALT6 CLCNKB TRPS1 BBS1 CSF2RB MPL PERP FAM149B1 COL1A1 HESX1 FCGR2A EDNRA IDS TRIM28 WDPCP CACNA2D1 CD79A PIK3R1 FGFR1 PIGP HNRNPU HPS6 SCNN1G MAP2K1 PDE6A CTSA CPT2 LMAN1 GPR101 SYNE1 TFAP2A COX2 RTL1 CCDC174 COQ2 NR2F2 OFD1 ND6 KCNH2 TSC2 KCNN3 RASGRP1 SP7 GBE1 NDP GATA1 COL3A1 POGZ ENPP1 POMGNT1 SEC23B TCTN3 GLI3 SREBF1 ITGA2B SMARCE1 POU3F4 GIGYF2 SIX6 F11 SEMA3A CDAN1 KIF5A MVK ARMC5 SDHA NDP PTPN14 HAMP CNGA1 PEX26 RYR2 HEXA TP53 HPS1 TET2 COL2A1 FBN1 SCN2A DMD GATA4 FMR1 NKX2-5 ELOVL4 DMRT3 FBLN5 GUCA1B NEK8 TMEM127 CLPB LDB3 RNASEH2C TWNK TBX20 CCR1 HADHA POR WNT4 ELAC2 MEG3 GP1BA TRDN SKI NEXN RAD51 DUSP6 OTUD6B USH2A NDUFA9 MMUT HYLS1 NPHP1 HBA1 CHRND PKP2 PDE6C XRCC2 FSCN2 VHL CCDC103 ERCC6 ZDHHC9 FARSB ODAD1 CYP11B1 ANK1 JAK2 NME8 AHR VHL SLC25A22 LETM1 SLC25A3 ELANE RFWD3 XPA GPC4 ITGA8 GNAQ CDKN1B GNAS ERCC8 C4A DYRK1B TRPC6 DNASE1 CA2 PROKR2 MLXIPL LZTR1 STX3 ALG12 AK2 IDH2 SLC52A2 PDE3A HELLPAR HSD3B2 GP9 SGSH BAZ1B ALG1 WT1 TANGO2 MID1 GP1BA XPC LDB3 NR2F2 DNAL1 TGFB3 SGCB CTSH CTSB DISP1 PRKAR1A TRNL1 UBE3B LCAT MAT2A FIBP CYP11B2 TNFSF11 DSP PET100 LMNA ABCA4 KCNA1 NFE2L2 EPHB2 SGCG PROC IARS2 KCND3 D2HGDH MGP TRDN NHLRC2 SOX9 PGAP2 NAGA PUF60 FKRP CTNNB1 SDHD KCNE2 RSPH9 NOTCH2 PACS1 GNAI2 NAA10 GNB5 GGCX KRT10 CD70 ND1 PIK3CD FMO3 ASS1 EXT1 USP9X PSAP GUCY1A1 LMNA WT1 PIEZO2 GJA5 STN1 DCX KCNE5 GPC1 PROKR2 EBP GNPTAB NLRP3 CFAP221 COA5 JUP GJB2 TP63 TBX3 AP1S1 HBA1 ROBO4 CERKL RPL26 DES EDA2R OFD1 CD81 TNFRSF13B POLG2 FIG4 DDX59 MYH7 NSD1 MTHFR HLA-DPB1 AGT RYR1 CFHR1 BRF1 SLC22A4 SLC25A20 MAPRE2 AKT1 RRAS2 EPHB4 MEN1 XRCC4 COX7B HSPG2 CEP290 CCDC115 LTBP2 DLK1 PROP1 SHOC2 FLT4 ACTB DGCR8 FBP1 NEB SLC35A1 EPAS1 COL1A1 MRAP SPECC1L PSEN2 CDH23 BLM PKD2 CDON PKD2 NPHP1 CST3 RAG1 SNRPB PRKG1 USB1 MYOCD GATA4 TMEM70 NDUFAF6 FLNA STAT2 ZNF365 MEFV PYGM RASA1 NEK1 SOX6 NF1 FKTN NF1 CSRP3 RPL35 HCN4 SRY MYOT TDGF1 GATA4 GGCX TAPT1 TMEM216 COX15 SLC4A1 ROM1 PAX8 COX1 MCM4 TINF2 CD40 TOPORS ERCC2 SDHC NAA10 MPL POT1 CR2 COL1A1 FGG FOXE1 NLRC4 TFRC TRIM37 EXT2 LMNA KMT2A ITGB3 TBX3 STXBP1 DNM2 NCKAP1L ATXN7 ACADVL SERPINF2 LDB3 TPM2 PLEKHM1 PAX3 ELP1 IRF8 RMRP TGFBR2 STAG2 UQCRFS1 LMX1B SALL4 CFAP300 SIX3 BMPR1A DDB2 IGHM GJA1 HPGD MEFV KCNH2 KCNQ2 PALLD RNASEH2B NDUFAF8 MSX1 NOTCH3 BCL6 ISCU ABCC8 ATP11A FAM111A DBH ODAD1 SDHC CHRNG HBB SALL4 CTLA4 ATP7A RNF213 LOX PIGV CP POLR1A NMNAT1 ALPK3 GPC3 WNT5A CYP26C1 PTEN PPARG BBS7 DDX6 ABCC9 PQBP1 COG5 LMNA ETHE1 LDLR DVL1 RASGRP1 CHD7 TTC12 VCL GABRA3 KRT18 PROC KLLN IARS1 GPI GAS1 KIF23 ACTA2 KCNQ1OT1 WIPI2 THPO FGF8 GLI2 LBR PLCB4 ARID1B BRAF DSP IDUA ANKRD1 BCOR IL12A MMUT SF3B4 PEX7 CFB SCN1B UMPS SERPIND1 PLOD3 KIAA1109 TERT XPC SMCHD1 CD96 MYH7 ACP5 SPEG NT5E DNAJC21 MYCN IGBP1 LMNB1 ACTC1 OTX2 RHBDF2 RTL1 ESS2 FYB1 EXOC6B RPS26 SLC39A4 PIGA MID1 ARL2BP EPHB4 SFTPB ODC1 ASCL1 TTPA PIGL PEX10 ND2 GBE1 TP63 JAK1 DHPS RAI1 XPNPEP2 DNAJB13 COL2A1 AGBL5 CPT2 PROM1 PALB2 IL12B SDHC PDE6G LEPR JAK2 FGG PIGT TSPYL1 STAMBP FASLG KLF13 PIEZO1 EZH2 EPB41 RUNX1 B2M CORIN SPTA1 NR3C2 MYH6 KLHL41 PROP1 ADA2 LIMK1 DSP RPL5 HMGA2 KRAS CCM2 NDUFAF1 ERCC3 IDH3A EP300 NDUFA6 MCCC1 DCLRE1C FARSA CDC42 PLCG2 ACTC1 STAT4 C2 VAC14 PKHD1 DMD ND3 SIN3A COL7A1 CYP3A5 BRAT1 ZMIZ1 NUP107 PTCH1 LMNB1 HNRNPK ND1 IGHM TNNI3K TGIF1 TUBB GJA5 POLG FLNC HAVCR2 SMARCC2 ERCC2 TXNL4A RAB23 CD3E MLH1 BCHE SULT2B1 DISP1 PEX1 LOX DES PIK3R2 BPTF TNNC1 PPP2CA RNF168 TMEM126B FSCN2 ARCN1 PIGV IDUA NKX2-5 IGH CYBB COL5A2 BCOR JAK2 SERPING1 SLC12A3 DOLK NEU1 TGIF1 ADA STAT3 FIBP B4GALT7 ZMIZ1 HLA-B HDAC4 ECE1 CYP17A1 TSC1 ATP6V0A2 A2ML1 DPM3 RP1L1 PKDCC RPS26 MEFV ORAI1 CLIC2 ITCH SEMA4A ASXL1 TRIM8 WNT4 RPS27 SURF1 UFD1 RAF1 SERPINF2 SRP54 SCNN1B GBA DKC1 MYH7 COG7 TCIRG1 ALOXE3 BBS5 SF3B4 LAMB3 VANGL2 MYPN GLI3 LIPT1 KANSL1 PTCH1 EIF2AK3 PPA2 NDUFB10 FBN1 ARL6 ABCA3 STEAP3 GCH1 UNC13D FGFR1 FZD4 HTRA1 SALL1 CPT1A HLA-DQB1 SMC1A PCCB NDUFAF4 FAM13A NEXN KCNN4 LARS2 CTU2 CYP21A2 HSD17B10 TWIST1 SMC3 COG1 ARPC1B FBN1 CALR GATA1 WDR1 ACTC1 PRNP RHAG DOLK RBPJ INF2 HLA-DRB1 HNRNPA1 PHOX2B DPH1 MYLK TMEM94 PRPF4 ADAR SARS2 HDAC8 MLH3 COL4A1 STAG2 LRAT CITED2 EFL1 KIAA1549 TERC BUB3 CRX ITGB3 NSD1 BOLA3 KIAA1549 ATF6 TRIP13 MEG3 PRDM16 KMT2C AIRE MED13L ATP7B AMMECR1 BCR BBS2 GLB1 ABCC8 ACAD8 DSP CYP7B1 MYPN DLL1 VHL EXTL3 SH3PXD2B KCNE5 ARL6 MAN2B1 COMT MYORG ARX EMG1 AIP CSRP3 RHAG RAG2 FCGR2A GJA5 TMEM67 BTNL2 ADAMTSL2 WNT3 DSP SOX18 PIGN PAFAH1B1 HGD ITPR1 FN1 FBN1 PIEZO1 ACTN2 COL1A1 YY1AP1 NPM1 ATP6V0A2 ZBTB16 AHCY EPG5 COL7A1 DDB2 SHH CACNA1C KIT EGFR OSGEP LAMA3 TBX2 SPECC1L IKZF1 SPECC1L SAMD9 LMNA YY1 PIK3C2A LMBRD1 ELN IFT172 PDSS2 DNAAF4 SH2B3 HBG1 NDUFA2 LZTFL1 MYO5B KCNJ11 EVC2 CEP120 SEC63 UNG PTEN MYC GATA4 SLC26A2 SCNN1G NKX2-1 PLOD1 PLEC DLL1 FHL1 MUC1 KYNU ABCA1 TTC8 IGH CLIP2 H19 APOB LAMA4 PLCB3 IL6 GNAQ KCNE1 IGF1R SLC25A4 DYNC2LI1 GNAS GDF1 MYOZ2 IRF5 DST LMX1B ARMC9 NRAS KCNE1 MEN1 SIX3 HJV MYD88 THOC2 PORCN SNRNP200 SOX11 GNB5 SHOC2 CKAP2L SDCCAG8 AP3B1 POLG PDGFB CBL APOC2 POLA1 COL2A1 LPL MLYCD SON TSC1 MIR17HG DVL3 RGR HESX1 LAMP2 RANBP2 SCNN1B ALX1 IFT122 GNPTG NRAS ARL6 FGB STK11 PEX2 MRPS22 GPX4 PCCA TTC37 DACT1 WT1 SMAD4 DAXX KRT14 PACS2 RPS15A RAF1 LRRC6 TRNW DYNC2I2 TNFRSF1B SHH PDE6B WNK1 PKP1 CHST14 TRNV TANC2 KIT FLNA NFIX SLC12A3 ACAD8 PRKCH TBXA2R TRAC TJP2 CCNO FGFR2 IDUA MGP KIT NDUFS3 GBA HRAS FAM161A KCNQ1 NOD2 NOD2 ADK MYCN SLC25A20 POU1F1 TRNH GAS1 AKT3 RAG1 PTPN11 SLC26A2 GATA2 STAR HMCN1 IDH3B SLC7A7 CACNA1S RARB GATA6 DPP6 FGA CBS SUFU TKFC PCCB CASP10 SRP54 SUGCT TNFRSF13C RPS17 B3GAT3 EBP ATP6 PLN TCAP CHRNA3 KCNH1 KRT5 MED12 MRAS LMOD1 TNFSF11 MYLK2 DCDC2 CAT FGFR3 CYP11B1 P2RY11 FLAD1 ADA XRCC4 MECP2 KCTD1 ND3 ACAD9 GBA CLCF1 NUMA1 TNFRSF11A FBXL4 ASXL1 GDF3 F5 MRAS ROR2 NUP107 HCN4 TNFRSF11A TWIST1 CEP290 IRF8 HLA-DRB1 DDX6 TAZ ZIC3 SEMA4A SCN4A NDUFV1 DNAAF1 LPL HOXA11 TRAF7 ERCC4 CACNA2D1 SPTB FGFR1 RBM20 NDUFA13 BCORL1 PIGW SMOC1 KRT5 ATRX ACTG2 FOXH1 COG7 MUC5B GATAD1 PRKCD HSD11B2 BGN STAG2 NPPA NDUFAF3 MYPN PSAP ABCA1 PTEN TNNI3 KCNJ2 RBM10 GANAB TACR3 CD244 PEX14 KANSL1 TNFSF12 MAP3K7 DBH COG2 SDHB IDS DNAAF3 DNAAF3 MC2R BSCL2 TNFRSF4 NAGS MYMK B2M LDLRAP1 CPN1 CAV1 DYRK1A MYOC HLCS ALPK1 KCNJ5 SCN5A SMO NONO FLT4 MAPT LEP CYP7A1 GPC6 CASQ2 TAB2 CPOX ITCH USP45 RYR2 DPM3 ZNF423 CRYAB CEP120 KIF1B SPIB NKX2-5 SELENOI PIGL FGFR1 NDUFS8 NDUFB8 CACNA1C SPEF2 NECTIN1 PBX1 AEBP1 POMT1 RAC2 JAK2 SCN5A COQ4 TBL2 BMP2 BBS2 GINS1 CFAP298 AKR1D1 TBX19 SYNE2 ACTA2 METTL5 DNAH5 WIPF1 POMT1 TLL1 CSNK2A1 MEG3 FGG LMNA KRIT1 OFD1 GATA6 IL12A TPM3 IL6 TRNT LMNA PPP2R1A SURF1 BRCA1 PSMB8 CACNA1C STAG2 CRKL SEC23A CACNA1D CDKN2B GATC SGCD LRP5 ALX3 TAZ COL5A1 MUC5B SEMA3E MRPL12 TCTN1 CDON PROS1 SRSF2 BAP1 FXN PIK3CA FOXRED1 DPP9 ARF1 RAF1 CD79B HEXB SDHC XRCC2 FGFR2 MYPN ZIC2 CALR ITGA7 LTBP2 RPGRIP1 TRIP11 APC SOX2 ABCA1 EXT2 NF1 SPINK5 DSG4 RTEL1 TNNI3 GPC3 TGFB2 SMAD4 DYNC2I1 TPM1 DMPK POMT2 DCDC2 SKI PIK3CA EBP WT1 ANKRD11 NR3C1 HFE SAMD9L TRNW SMC1A KCNE2 ICOS RTTN RB1 HGD F5 FOXF1 CHST14 GLB1 KRAS NCF1 SMAD6 PTCH1 IL2RG B3GALT6 SF3B4 GLI2 RP1L1 OTULIN F8 TET2 SEC23B ZNF148 COX3 OBSL1 WRAP53 ACTN2 PAX3 NDUFV1 ATP7A HGSNAT GLUL CARMIL2 PDGFB ABCC6 STIM1 KDSR DGUOK PTEN TERT FAT4 ALG1 PSEN2 MYL4 COX14 ITGB3 IGFBP7 PHOX2B CHD7 RBM8A ROM1 NLRC4 F10 PTGIS TMEM70 POLD1 EMD TDP2 CACNA1S PRKCSH NUP155 ALPL PKLR TRNL1 CTC1 PEX5 SDHB GATA6 MYPN ALG10B MEN1 NDUFV2 SDHD CCDC39 HEPHL1 HSD17B10 WHCR ACSL4 GP6 MTMR14 COX1 NAA10 FGFR3 EP300 TNNI3 GMPPB NDUFS4 LZTFL1 CTNNB1 INPP5E KCNJ8 HCRT HLA-DRB1 DKC1 TERT SCN10A GGCX KRT8 ERCC4 SFTPB LMBR1 NDUFAF1 RFT1 CCDC65 HDAC8 HBA1 POMT1 SEC61A1 SLC25A11 FLII CLIC2 CPT2 ATP6 DHCR24 COA8 CAV3 LFNG RLIM SUZ12 MARS2 NEU1 XIAP HLA-B BTD SREBF1 FGFR2

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook